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ABSTRACT 
 
INTRODUCTION: A significant proportion of Hodgkin lymphoma (HL) patients refractory to first-
line chemotherapy or relapsing after autologous transplantation are not cured with currently 
available treatments and require new treatments. The PI3K/AKT and RAF/MEK/ERK pathways 
are constitutively activated in the majority of HL. These pathways can be targeted using the AKT 
inhibitor perifosine (Æterna Zentaris GmBH, Germany, EU), and the RAF/MEK/ERK inhibitor 
sorafenib (Nexavar®, Bayer, Germany, EU). We hypothesized that perifosine in combination with 
sorafenib might have a therapeutic activity in HL by overcoming the cytoprotective and anti-
apoptotic effects of PI3K/Akt and RAF/MEK/ERK pathways. Since preclinical evidence supporting 
the anti-lymphoma effects of the perifosine/sorafenib combination are still lacking, the present 
study aimed at investigating in vitro and in vivo the activity and mechanism(s) of action of this two-
drug combination. 
METHODS: Three HL cell lines (HD-MyZ, L-540 and HDLM-2) were used to investigate the effects 
of perifosine and sorafenib using in vitro assays analyzing cell growth, cell cycle distribution, gene 
expression profiling (GEP), and apoptosis. Western blotting (WB) experiments were performed to 
determine whether the two-drug combination affected MAPK and PI3K/AKT pathways as well as 
apoptosis. Additionally, the antitumor efficacy and mechanism of action of perifosine/sorafenib 
combination were investigated in vivo in nonobese diabetic/severe combined immune-deficient 
(NOD/SCID) mice using tumor growth rates and survival as endpoints. 
RESULTS: While perifosine and sorafenib as single agents exerted a limited activity against HL 
cells, exposure of HD-MyZ and L-540 cell lines, but not HDLM-2 cells, to perifosine/sorafenib 
combination resulted in synergistic cell growth inhibition (40% to 80%) and cell cycle arrest. Upon 
perifosine/sorafenib exposure, L-540 cell line showed significant levels of apoptosis (up to 70%, P 
≤.0001) associated with severe mitochondrial dysfunction (cytochrome c, apoptosis-inducing factor 
release and marked conformational change of Bax accompanied by membrane translocation). 
Apoptosis induced by perifosine/sorafenib combination did not result in processing of caspase-8, -9, 
-3, or cleavage of PARP, and was not reversed by the pan-caspase inhibitor Z-VADfmk, supporting 
a caspase-independent mechanism of apoptosis. In responsive cell lines, WB analysis showed that 
anti-proliferative events were associated with dephosphorylation of MAPK and PI3K/Akt 
pathways. GEP analysis of HD-MyZ and L-540 cell lines, but not HDLM-2 cells indicated that 
perifosine/sorafenib treatment induced upregulation of genes involved in amino acid metabolism 
and downregulation of genes regulating cell cycle, DNA replication and cell death. In addition, in 
responsive cell lines, perifosine/sorafenib combination strikingly induced the expression of tribbles 
homologues 3 (TRIB3) both in vitro and in vivo. Silencing of TRIB3 prevented cell growth reduction 
induced by perifosine/sorafenib treatment. In vivo, the combined perifosine/sorafenib treatment 
significantly increased the median survival of NOD/SCID mice xenografted with HD-MyZ cell line 
as compared to controls (81 vs 45 days, P ≤.0001) as well as mice receiving perifosine alone (49 days, 
P ≤.03) or sorafenib alone (54 days, P ≤.007). In addition, perifosine/sorafenib treatment had no 
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effect on HDLM-2 nodules, but significantly reduced L-540 nodules with 50% tumor growth 
inhibition (P ≤.0001), compared to controls. In mice bearing subcutaneous nodules generated by HD-
MyZ and L-540 cell lines but not HDLM-2 cell line, perifosine/sorafenib treatment induced 
significantly increased levels of apoptosis (2- to 2.5-fold, P ≤.0001) and necrosis (2- to 8-fold, P 
≤.0001), as compared to controls or treatment with single agents. 
CONCLUSIONS: Perifosine/sorafenib combination resulted in potent anti-HL activity both in vitro 
and in vivo. These results warrant clinical evaluation in HL patients. 
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1.1 HODGKIN LYMPHOMA 
 
Hodgkin lymphoma (HL), more commonly known as Hodgkin disease, is an uncommon neoplasm 
arising from B lymphocytes with an estimated 8490 new cases in the United States in 2010.1 It 
was first described by Thomas Hodgkin in 1831. HL accounts for approximately 15% of all 
lymphomas and is common in young adults. The overall incidence rate has been steady since the 
1970s. The outcome of patients with all stages of HL has improved dramatically during the past few 
decades mainly because of the use of intensive combination chemotherapy agents and involved-
field radiation therapy. HL is one the most treatable and curable lymphomas. The challenges for the 
primary care providers are to monitor the long-term side effects of the intensive treatments and to 
improve patient’s quality of life. The majority of HL patients present with lymphoadenopathy, 
typically in the supraclavicular or lower cervical region. In the absence of treatment, the disease 
follows a predictable course spreading from one group of lymph nodes to those adjacent in a 
systematic process. Mediastinal masses are frequent and patients often present with chest 
discomfort and coughing or breathlessness. Approximately a quarter of HL cases manifest systemic 
B symptoms including fatigue, weight loss, intermittent fevers and itchy skin associated with night 
sweats. Diagnosis is usually made by histological examination of an excisional biopsy of an 
enlargened lymph node.  
The disease is then staged using the Ann Arbor staging system (Table 1.1) developed in 19712 and 
modified in 1989.3 This system defines the extent of disease progression and helps predict prognosis 
and direct treatment. Four stages are described followed by the letter A or B, indicating the absence 
(A) or presence (B) of B symptoms. 
 
Table 1.1 The Ann Arbor staging system for HL. 
 
STAGE SYMPTOMS 
1 Involvement of one lymph nodes or lymphoid structure  
2 Involvement of two or more lymph nodes on the same side of the diaphragm  
3 Involvement of lymph nodes on both sides of the diaphragm  
4 Involvement of extranodal site(s), with or without associated lymph node involvement  
 
Treatment is by chemotherapy, radiotherapy or a combination of both. High-dose myeloablative 
chemotherapy followed by autologous stem cell transplantation (SCT) has an established role in the 
management of patients with relapsed HL. Autologous SCT has significantly increased the survival 
of patients with relapsed HL.4,5 However, a significant proportion of relapsed HL (50 – 60%) patients 
are not cured with currently available therapeutic strategies, thus the development of new drugs 
will address a significant unmet medical need.6,7 
 
Diagnosis rests on the identification of typical large multinucleated cells, the Reed-Sternberg (RS) 
cells, surrounded by a heterogeneous cellular infiltrate composed of lymphocytes, histiocytes, 
eosinophils, plasma cells and polymorphonuclear leukocytes. RS cells measure 20 – 60 µm in 
diameter and have at least two nuclei with prominent acidophilic or amphophilic nucleoli (Figure 
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1.1).8 Hodgkin (H) mononuclear cells display similar cytological features to RS cells, and these cells 
are collectively referred to as HRS cells.8 Cells with morphology similar to RS cells have been 
identified in both infectious mononucleosis and non-Hodgkin’s Lymphoma, but the presence of the 
specific heterogeneous cellular background is unique to HL. Unusually for human lymphomas, the 
neoplastic cells make up a very low proportion (<1%) of the tumour cell population and this, in the 
past, has restricted a detailed investigation of these cells.9,10 
 
 
 
Figure 1.1: Hodgkin and Reed–Sternberg (HRS) cells in their microenvironment. This figure illustrates the 
typical histological and immunohistochemical picture seen in classical Hodgkin’s lymphoma. (A) 
Haematoxylin and eosin staining of a case of nodular sclerosis Hodgkin’s lymphoma. Several large HRS cells 
are visible, one of them in the centre of the picture. (B) CD30 immunostaining (red) highlighting several large 
CD30+ HRS cells. (C) CD3 staining showing the dominant T-cell infiltrate and a ring of T cells around an HRS 
cell in the centre. 
 
1.2 CROSSTALK BETWEEN CELLS: THE IMPORTANCE OF  CYTOKINES 
AND CHEMOKINES IN HL 
 
Cytokines and chemokines are low–molecular weight proteins with a wide variety of functions that 
work either in a paracrine manner to modulate the activity of surrounding cells or in an autocrine 
fashion to directly affect the cells that produce them. Specifically, these autocrine and paracrine 
interactions lead to the particular cellular composition found in HL and contribute to the 
proliferation and antiapoptotic phenotype of HRS cells (Figure 1.2). Although the cytokine and 
chemokine milieu in HL tissues is complex and interactive, a clear understanding of this biology 
will be clinically relevant in the future as therapies are developed that disrupt the crosstalk between 
malignant cells and the microenvironment. Hence, improved insight into the biology will be critical 
to introducing these novel biologic treatments into clinical practice. This section focuses on the 
involvement of cytokines in the formation of the microenvironment and highlights how, in return, 
HRS cells receive signals from the microenvironment through surface receptors. The clinical and 
pathologic features of HL reflect an abnormal immune response that is thought to be the result of 
expression of a variety of cytokines and chemokines by the HRS cells, altering the composition and 
function of the cells in the surrounding microenvironment and shaping the specific histopathologic 
appearance of the lymph node.11 Moreover, the reactive cells in the microenvironment produce 
specific cytokines and chemokines that help maintain and even amplify the intense inflammatory 
A B C 
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reaction.12 In addition to the variability of cytokine expression in the different HL subtypes, Epstein-
Barr virus (EBV) positivity also influences the relative expression of certain cytokines (eg, CXCL10, 
CXCL9, CCL5, and CCL3).13 
 
  
Figure 1.2: Schematic of the crosstalk between malignant Hodgkin Reed-Sternberg (HRS) cells and the tumor 
microenvironment in classical Hodgkin’s lymphoma. In the center, a bi-nucleated HRS cell is shown expressing 
characteristic surface molecules as well as secreted cytokines and chemokines. Surrounding the HRS cells are 
cell types representative of the non-neoplastic cells attracted and activated by these molecules. The cells in the 
microenvironment themselves express a variety of chemokines and cytokines that further shape the reactive 
infiltrate and provide signaling for HRS cells. Only the main activating and inhibitory functions (arrows) of 
predominantly membrane-bound (purple triangles) and secreted molecules mediated by surface receptors 
(pink) are illustrated; other interactions exist. IL, interleukin; FGF, fibroblast growth factor; TNF-!, tumor 
necrosis factor !; LT-!, lymphotoxin !; TGF-#, transforming growth factor #; BAFF, B-cell activating factor; 
APRIL, a proliferation-inducing ligand; BLC, B lymphocyte chemoattractant; TNFR, tumor necrosis factor 
receptor; FASL, Fas ligand; MEC, mucosae-associated epithelial chemokine; Treg, T regulatory cell; TH, T 
helper cell; MDC, macrophage-derived chemokine; Gal-1, galectin-1; PDL, programmed cell death 1 ligand; 
IFN-", interferon gamma; NK, natural killer. 
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1.3 CLASSIFICATION OF HODGKIN LYMPHOMA 
  
The first comprehensive classification of HL, then known as Hodgkin’s disease, was the Rye 
Classification.14 The proportion of HRS cells in the tumour cell population and the nature of the 
infiltrate allowed four HL subgroups to be identified: nodular sclerosis (NSHL), mixed cellularity 
(MCHL), lymphocyte-depleted (LDHL) and lymphocyte-predominant HL. The International 
Lymphoma Study Group was founded in Berlin in 1990 and published the Revised European-
American Classification of Lymphoid Neoplasms (REAL) in 1994.15 This system took into account 
the morphological, immunological, molecular and genetic components of lymphomas and 
leukaemias and also recognised entities commonly diagnosed in routine practice. The three major 
classified groups were HL, B-cell lymphomas/leukaemias and T-cell lymphomas/leukaemias. 
Diseases were initially classified by their cell of origin and then further subdivided by their 
histological grade. This classification was expanded upon by the Society for Hematopathology and 
the European Association of Hematopathologists for the World Health Organisation (WHO).16 The 
WHO classification encompasses haematopoietic and lymphoid neoplasms and is in global use. Two 
distinct groups of HL are characterised in this classification, classical HL (cHL) and nodular 
lymphocyte-predominant HL (NLPHL), with the former being further subdivided into NSHL, 
MCHL, LDHL and lymphocyte-rich classical HL (LRCHL). NLPHL and cHL differ in the origin of 
their tumour cells, their clinical behaviour and their immunophenotype.17 Immunophenotyping is 
an important diagnostic tool for differentiating between these two HL groups. In cHL, HRS cells are 
usually positive for CD15 and CD30, and either positive or negative for CD20.18 In NLPHL cells are 
usually negative for CD15 and CD30, but positive for CD20.19 
 
1.4 ORIGIN AND CLONALITY OF HRS CELLS 
  
1.4.1 cHL-derived cell lines 
  
The establishment of permanent cell lines has allowed the biological characterisation of many 
human neoplasms, but only a few cell lines have been derived from cHL cases: CO, HDLM-2, HD-
MyZ, Ho, KM-H2, L-1236, L-428, L-540 and L-591. The origins of some are, however, dubious (eg, 
HD-MyZ) and some (eg, CO) have been reported to have been cross-contaminated with the T-cell 
acute lymphoblastic leukaemia cell line, CCRF-CEM.20,21 The remainder have generally been derived 
from body fluids extracted from patients with end-stage disease. Only the L-1236 cell line has been 
shown to definitely be derived from HRS cells.22 
 
1.4.2 The origin of HRS cells 
 
Analysis of established cHL-derived cell lines has shown that HRS cells do not display specific 
lineage markers, and often coexpress markers typical for a number of different hematopoietic cell 
types. Developments in micromanipulation and microdissection procedures, coupled with single 
cell polymerase chain reaction (PCR) assays for immunoglobulin (Ig) gene rearrangements, have 
enabled the characterisation of single HRS cells. Ig gene rearrangements involve variable, diversity 
and joining regions and are unique to B-cells. These rearrangements are therefore distinct markers 
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which can be used to determine the origin of B lineage cells and assess clonality. Several studies 
have identified Ig gene rearrangments within HRS cells, micromanipulated from cHL cases, which 
indicates that these cells originate from B-cells.23-25 Germinal centres (GCs) are specialised 
microanatomical structures, within secondary lymphoid follicles, which develop from antigen-
specific B-cells that have clonally expanded during immune responses.26 Upon entering the GC, B-
cells automatically begin the cell death program and are only able to escape this process if they 
display key positive selection signals. They undergo several rounds of proliferation, somatic 
hypermutation (SHM) and selection in order to develop high affinity antigen receptors (Figure 1.3). 
The process of SHM is known to take place in secondary lymphoid organs, within the dark zone of 
the GC, during T-cell-dependent immune responses (Figure 1.3). SHMs are detectable in the 
majority of Ig gene rearrangements. Non-functional gene rearrangements, resulting from SHM, 
were identified within HRS cells micromanipulated from approximately 25% of cHL cases.23 Any 
GC B-cells acquiring non-functional gene rearrangements within the GC undergo apoptosis instead 
of differentiation, and do not develop into memory B-cells or plasma cells. The presence of SHMs in 
HRS cells suggested, therefore, that these cells may derive from preapoptotic B-cells that have 
gained crippling mutations preventing them from undergoing antigenic selection. The expression of 
T-cell markers in a small proportion of HL cases suggested that some HRS cells could originate from 
T-cells.25,27,28 In one study HRS cells with a cytotoxic T-cell phenotype were isolated from 3 cHL 
cases.29 Germline configuration of IgH and T-cell receptor (TCR)-loci, and both Ig and TCR-gene 
rearrangements were investigated. In two of the HL cases, cytotoxic T-cell markers were identified 
in the HRS cells and the authors suggested that these cells were derived from mature GC B cells that 
aberrantly express T-cell markers. In the third HL case a typical T-cell gene rearrangement pattern 
was observed in the HRS cells indicating these cells were of T-cell origin. TCR gene rearrangements 
were detected in 2 of 13 T-cell marker-expressing HL cases in a separate study.25,28 The remaining 11 
HL cases in this study were of B-cell in origin. This demonstrated that it is possible for HRS cells 
with a T-cell phenotype to have a B cell genotype, and that in the vast majority of cases HRS cells are 
derived from B-cells. 
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Figure 1.3: Cellular origin and B-cell differentiation within secondary lymphoid organs eg lymph nodes and 
spleen.30 The marginal zone (MgZ) contains post-germinal centre (GC) B-cells and naïve B-cells. The mantle 
zone (MnZ) is formed by naive B-cells, which are replaced by proliferating B-cells and displaced to the outside 
of the primary B-cell follicle. Naive antigen-activated B-cells are transferred into primary B-cell follicles in 
lymph nodes, known as GC, where they become proliferating GC B-cells within the dark zone. A – V-region 
gene recombination in the bone marrow; B – clonal expansion; C – somatic hypermutation; D – mutations 
increasing antigen affinity; E – class switching; F – selection; G – differentiation. 
 
From the unique morphology and the frequent identification of additional chromosomal copies in 
both the multinucleated RS and the mononucleated H cells, it was proposed that these cells may 
arise from fusion between a B-lymphocyte and a dendritic cell. A study of 5 cases of HL with two 
known rearranged IgH alleles sought to investigate this theory.31 The majority of B-cells carry two 
rearranged IgH alleles whereas IgH alleles in non-B-cells show a germline configuration. The 
presence of additional IgH alleles in a germline configuration would therefore be consistent with a 
cell fusion between a B-cell and a non-B-cell. Single HRS cells were micromanipulated from selected 
HL cases and amplification reactions were performed to identify rearranged alleles in IgH and T-cell 
receptor VDJ and DJ genes. None of the cases showed evidence of additional IgH or TCR alleles to 
those already identified indicating that HRS cells do not represent fusions of B-cells.  
 
1.4.3 The phenotype of HRS cells 
 
HRS cells have a unique phenotype unrelated to any hematopoietic cell type. They usually expre 
some T-cell markers, dendritic cell markers (eg, fascin, thymus and activation-regulated chemokine 
(TARC)), myeloid cell markers (eg, CD15), plasma cell markers (eg, CD138) and some B-cell markers 
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(eg, Pax-5). Other B-cell markers (eg, CD20 and Oct-2) and B-cell receptors are rarely identified on 
HRS cells. Hence, the revelation that HRS cells originated from B-cells prompted a large gene 
expression study comparing gene expression profiles of HL-derived cell lines and normal B-cells.32 
A global downregulation of B-cell specific genes within HRS cells was revealed. It was suggested 
that the loss of B-cell gene expression could result in these cells not being recognised as B-cells and 
failing, therefore, to be identified for apoptosis, the mechanism within the GC by which defective B-
cells are normally apoptosed.  
  
1.5 SIGNALING PATHWAYS ACTIVE IN HRS CELLS 
 
Cancer cell proliferation, apoptosis, angiogenesis, invasion, and metastasis are regulated by an 
interconnecting network of cellular signaling pathways involving extracellular ligands, 
transmembrane receptors, intracellular signaling protein kinases, and transcription factors.33 These 
intracellular signaling effectors are modulated by external factors, such as epigenetic changes, 
oncogenic mutations, molecular chaperones, and ubiquitin-proteasome pathways. Insights into 
these complicated intracellular processes have exposed many novel cancer targets for which 
chemotherapeutic agents may be developed (Figure 1.4). 
Figure 1.4: Signaling pathways involved in the proliferation, angiogenesis, and differentiation in neoplasms 
with the targets amenable to therapeutic interventions in cancer therapy. Membrane-bound human epidermal 
growth factor receptors (HER), c-MET, and insulin-like growth factor 1 receptor (IGF-1R) mediate mitogenic 
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signals from extracellular ligands, such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), and 
insulin growth factors (IGF), respectively. The Ras/Raf/MEK/Erk (mitogen-activated protein kinase, MAPK) 
and PI3k/Akt/mTOR pathways are major intracellular axes that regulate intracellular signaling traffic. DNA 
methytransferases (DNMT) and histone deacetylases (HDAC) are “epigenetic switches” that modulate the 
expression of oncogenes and tumor suppressor genes. The agents targeting the signaling proteins are indicated 
in boxes. 
 
The heterodimeric Nuclear factor kappa B (NFkB) is a key transcription factor involved in many 
inflammatory and immunologic processes. Activation of several cell-surface receptors (eg, CD40) 
leads to degradation of the NFkB inhibitor IkB! or other members of the IkB family, that normally 
bind to NFkB and prevent its translocation into the cell nucleus. Inactivation of IkB is mediated by 
IkB kinases, which phosphorylate IkB and cause its ubiquitination and degradation. Upon 
degradation of IkB, NFkB can move into the nucleus and activate expression of multiple genes. 
NFkB (p65/RelA) was first described in 1996 to be constitutively active in Hodgkin lymphoma cell 
lines34 and to be critical for HRS cell survival in vivo in Severe combined immunodeficiency (SCID) 
mice.35 NFkB has been shown to mediate both proliferative and anti-apoptotic gene expression 
programmes in HRS cells.36 Inhibition of NFkB activity and induction of spontaneous cell death in 
HL cell line by overexpression of an IkB! superrepressor has provided further evidence that NFkB 
is critical for HRS cell surivival.36 NFkB therefore might be regarded as a transforming master switch 
for HRS cells in HL, although constitutive NFkB activation is not a specific feature of HRS cells but 
is also characteristic for inflammatory disease and other lymphomas, such as a subset of diffuse 
large B-cell lymphomas. There are various explanations for NFkB up-regulation in HRS cells: gene 
amplification of c-rel;37,38 activation of cell-surface receptors such as CD30,39 CD40,40 RANK,41 or 
Notch1;42 expression of viral latent membrane proteins 1 and LMP2a in EBV-positive cases; or loss-
of-function mutations of the NFkB suppressor IMBN or IMBP.  
 
Upon TNFR ligation, NFkB activation is induced via TRAF signaling39,43 and the mitogen-activated 
protein kinase (MAPK) pathway.44 It has been shown that activation of the MAPK/Extracellular 
signal-regulated kinase (MEK) leads to phosphorylation of downstream ERK in HRS cells, thus 
promoting cell survival.44 Inhibition of Extracellular Related Kinase (ERK) phosphorylation was 
efficient ininhibiting ligand-induced cell survival in HRS cell lines. Of note, CD30 signaling has 
recently been linked to the non-canonical NFkB activation pathway involving RelB/p52 in HRS 
cells.45 
 
Analysis of the Phosphoinositide 3-kinase (PI3K)/AKT signaling cascade revealed constitutive 
activity of this pathway in HRS cell lines, which has been linked to IL6 secretion and expression of 
EHG homeobox gene HLXB9 of HRS cells in vitro.46 It has been demonstrated that targeting of the 
PI3K/AKT pathway with small molecule inhibitors might be of potential use for future treatment 
strategies in patients with Hodgkin lymphoma (Table 1.2).47  
 
The activator protein 1 (AP-1) complex is formed by hetero or homodimers of jun, Fos, and ATF 
family proteins. In Hodgkin lymphoma and also in anaplastic large-cell lymphoma but not in other 
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lymphoma entities, c-jun and junB have been decribed to be aberrantly expressed in the malignant 
cell population.48 C-jun seems to be the major transactivating force of the constitutive AP-1 complex. 
Its activity in HRS cells is independent of JNK but relies on an unknown autoregulatory mechanism, 
whereas junB activity is NFkB dependent. Both c-jun and junB support proliferation of HRS cells, 
possibly via induction of cyclin D2 and c-MET expression.48 
 
Notch1 is a cell transmembrane receptor that upon ligand binding is cleaved, so that the 
intracellular domain can translocate into the nucleus and function as a transcription factor.49 Notch1 
signaling plays an important role in various cell fate decisions, including B- and T-cell development. 
In Notch1 expressing lymphoid precursors B-cell development is suppressed and T-cell 
differentiation is promoted.49 With this background, it was surprising that strong Notch1 expression 
was detected in B-cell-derived HRS cells.42 The Notch1 ligand Jagged1 is expressed in HRS cells and 
also in other cells in the tumor tissue, suggesting that Notch1 is activated and functioning in HRS 
cells.42 This is supported by studies with HL cell lines, which showed that activation of Notch1 
promotes cell proliferation and survival,42 although another study could not verify the growth-
promoting effect of Notch1 activation in a HL line.50 The aberrant expression of Notch1 in HRS cells 
may also contribute to the lost B-cell phenotype of HRS cells discussed above, although the B-cell-
specific target genes inhibited by Notch1 are still largely unknown. 
 
Many cytokines signal through the Jak/STAT pathway. Upon cytokine receptor activation, Jak 
kinases become activated, and these can then phosphorylate members of the STAT family of 
transcription factors. Posphorylated STATs can enter the cell nucleus and activate transcription of 
target genes. In HRS cells, STAT3, STAT5a, and STAT6 are expressed and constitutively 
activated.51,52 The activation of STAT6 is likely mediated by an autocrine stimulation loop, because 
this factor is activated by IL13R signaling, and HRS cells express both IL13 and the IL13R.11,52 For 
STAT5a, it has been shown that both its expression as well as its activation is positively regulated by 
NFkB activitiy in HRS cells.51 STAT signaling is presumably important for HRS cell proliferation, 
because inhibition of IL13 signaling or STAT3 activity in HL cell lines inhibits cell proliferation.53,54 
Once again, this probable oncogenic addiction of cHL to the members of the JAK-STAT cascade 
makes it an additional, crucial, targetable pathway (Table 1.2). 
 
Based on gene expression profiling studies, aberrant expression of multiple receptor tyrosine 
kinases, which are not normally expressed by B-cells, was recently identified in Hodgkin 
lymphoma.55 The coexpression of several receptor tyrosine kinases, including PDGFRA, DDR2, 
EPHB1, RON, TRKA, and TRKB, was most pronounced in cHL, but was also identified in 
lymphocyte-predominant HL. Activation of these tyrosine kinases was implicated by the 
phosphorylation of several kinases themselves and by an elevated phospho-tyrosine content of the 
HRS cells in a considerable fraction of cases.55 The receptor tyrosine kinase activity seems not to be 
due to somatic mutations, but to ligand-induced activation, as the ligands for several of the tyrosine 
kinases were detected in the cells surrounding the HRS cells or in the HRS cells themselves, 
indicating both paracrine and autocrine activation mechanisms.55 A coexpression and activation of 
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multiple receptor tyrosine kinases appears to be unique to HL among lymphoid malignancies and 
suggests that this activation may play a central role in HL pathogenesis. However, the critical 
downstream targets of the kinase activities remain to be identified. 
 
In summary, multiple signaling pathways are aberrantly activated in HRS cells in vitro and in vivo 
and critically contribute to the proliferation and survival of the HRS cells (Figure 1.5). For some of 
the signaling pathways mechanisms for their aberrant and constitutive activation were elucidated in 
recent years. Future functional studies using knockdown experiments such as RNA interference 
technology might help to clarify the relative contribution of each of the mentioned pathways for the 
pathogenesis of Hodgkin lymphoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Pathway activation in HRS cells through signaling from the microenvironment. Soluble and 
membrane-bound signaling molecules produced by reactive cells (paracrine activation) activate the Janus 
kinase–signal transducer and activator of transcription signaling (JAK-STAT) and canonical and alternative 
NFkB pathways and receptor tyrosine kinases. For the JAK-STAT signaling pathway, the most commonly 
expressed ILs, IL receptors, and activated STATs are shown. For the NFkB pathway, only the principal 
activation cascades are shown, and inhibitor of k kinase (IKK) complex activation by other kinases are 
described. Downstream signaling of receptor tyrosine kinases is shown using the example of tyrosine kinase 
receptor A (TRKA) and illustrating the Ras and Akt pathways; other signal transduction pathways exist. GM-
CSF, granulocyte macrophage colony-stimulating factor; RANKL, receptor activator of NFkB ligand; TNF-!, 
                                                                                                                                                                  
Introduction - 17  
tumor necrosis factor !; LT-!, lymphotoxin !; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating 
factor; HGF, hepatocyte growth factor; NGF, nerve growth factor; TACI, transmembrane activator and CAML 
interactor; BCMA, B-cell maturation antigen; c-MET, mesenchymal epithelial transition factor; DDR, discoidin 
domain receptor tyrosine kinase; TYK2, tyrosine kinase 2; RIP, receptor-interacting protein; TRAF, TNF 
receptor–associated factor 1; MAP3K, mitogenactivated protein 3 kinase; SHP2, Src homology 2 domain–
containing tyrosine phosphatase; SOS, son of sevenless homolog 1 (Drosophila); GRB2, growth factor receptor–
bound protein 2; PI3K, phosphoinositide 3-kinase; ERK, extracellular signal-regulated kinase; MEK, MAP-ERK 
kinase; PDK, 3-phosphoinositide–dependant protein kinase; BAD, BCL2-associated agonist of cell death; MDM, 
mouse double minute; mTOR, mammalian target of rapamycin. 
 
Table 1.2: Overview of selected novel targeted therapeutic strategies being studied for the treatment of classical 
Hodgkin lymphoma  
 
TARGETS AGENTS MECHANISM OF ACTION 
CD20 
Rituximab 
Ibritumomab 
tiuxetan 
Antibody-dependent cytotoxicity (ADCC) 
Radioimmunotherapy 
Apoptosis facilitation through opening of store-
operated 
Ca++ channels 
cHL stem cell depletion? 
CD25 
(IL2R!) 
90Y-Daclizumab 
DAB486IL-2 
RFT5-SMPT-dgA 
Radioimmunotherapy 
Cytotoxin delivery 
CD30 
MDX-060 
SGN-30 
MDX-1401 
SGN-35 
H22xKi-4 
131I-Ki-4 
Ki-4.dgA 
ADCC 
Radioimmunotherapy 
Cytotoxin delivery 
CD40 SGN-40 Chir12.12 
ADCC 
Abolishment of CD40 signaling 
CD80 Galximab ADCC 
EBV EBV-specific cytotoxic lymphocytes Cytotoxicity against virus infected HRSC? 
HSP90 
7-allylamino- 
17-demethoxy-geldanamycin 
(17-AAG) 
Abolishment of NF-kB, Akt and Jak stabilization 
by HSP90 
IkB! Bortezomib 
Blocking IkB! degradation → decreased NF-kB 
signaling 
Blocking anti-apoptotic mechanisms 
Inhibitor 
of NF-kB 
kinase (IKK) 
As2O3 Inhibition of IKK → decreased NF-kB signaling 
IL13 TNX-650 CAT-354 Abolishment of growth promoting loops 
IL4R IL4-cytotoxin Cytotoxin delivery 
JAK-STAT 
17-AAG 
Tyrphostin AG17 
ISIS 345794 
Abolishment of stimulating signaling pathways 
by 
inhibiting STAT phosphorylation or abolishment 
of Jak stabilization by HSP90 
 
mTOR/Raptor 
 
Sirolimus 
Everolimus 
 
Stabilization of IkB! → decreased NF-kB 
signaling 
Inhibition of angiogenesis 
PI3K LY294002 QLT394 Abolishment of the PI3K/Akt survival pathway 
VEGF Bevacizumab 
Abolishment of VEGF-VEGFR2 growth 
promoting 
loops Inhibition of angiogenesis 
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1.6 PI3K/AKT PATHWAY 
 
1.6.1 Phosphoinositide 3-kinase (PI3K) family  
 
PI3Ks are a family of enzymes, which phosphorylate the 3’-OH position of the inositol ring of 
phosphoinositides. They have been divided into three classes on the basis of structural features and 
in vitro lipid substrate specificity (Figure 1.6).56-58  
 
Class I PI3Ks form heterodimers, which consist of one of the four closely related ∼110 kDa catalytic 
subunits, and an associated regulatory subunit belonging to two distinct families. In vitro they are 
capable to convert PtdIns to PtdIns-3-P, PtdIns-4-P to PtdIns(3,4)P2, and PtdIns(4,5)P2 to 
PtdIns(3,4,5)P3, but the in vivo substrate is PtdIns(4,5)P2.59 Class I PI3Ks are activated by a large 
variety of cell-surface receptors, comprising growth factor receptors as well as G protein-coupled 
receptors.60 
 
Class II PI3Ks are capable to phosphorylate PtdIns and PtdIns-4-P in vitro, but their relevant in vivo 
substrates are still under investigation. This class of large (170–200 kDa) enzymes has three 
members, all characterized by a C-terminal C2 homology domain, which is Ca2+-insensitive due to 
the lack of a conserved aspartate residue.61 No adaptor molecules for class II PI3Ks have been 
identified so far. Although class II PI3Ks have been localized to the trans-Golgi network and low-
density microsomes, their mode of action is still poorly understood. Mainly the PI3KC2! isoform 
has been reported to associate with clathrin and has been attributed a role in clathrin assembly and 
clathrin-mediated vesicular trafficking.62,63 A growing list of stimuli was described to activate class II 
PI3Ks, including chemokines (MCP-1), cytokines (leptin and TNF!), LPA, insulin, and other data 
show association of the class II enzymes with EGF-, PDGF- and SCF-receptors. Recently, it was 
demonstrated that PI3KC2# might be involved in LPA-induced cell migration of ovarian and 
cervical cancer cells.64 
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Figure 1.6: Domain structure of phosphoinositide 3-kinases (PI3Ks), PI4Ks and PI3K-related proteins' catalytic 
and regulatory subunits. All catalytic subunits of the depicted kinases share a core catalytic domain (PI3Kc), 
which contains the ATP-binding site. In the case of TRRAP this domain has no kinase activity due to mutations 
in conserved residues (shown as stars). At their N-terminus, the catalytic domains of PI3K class I have a 
regulatory subunit binding domain (p85B binds p85/55/50 regulatory subunits; pRegB binds p101 and 
p84/87PIKAP proteins), followed by a Ras-binding domain (RasB), a C2 domain (protein kinase C homology 
domain 2) and a PI3K accessory (helical) domain (PI3Ka). PI3K" contains interaction sites for #" subunits of 
trimeric G proteins in the pRegB and the PI3Kc domains. PI3Ks of the class II do not have a known adaptor 
subunit-binding site in front of their RasB site, but display two to three proline-rich (P) stretches, as well as a PX 
(phox) and an additional C2 domain at the C-terminus. The catalytic subunit of the class III enzyme Vps34 is 
composed only of the C2, PI3Ka and PI3Kc domains. The PI3K-related proteins are large enzymes sharing only 
the PI3Kc domain with PI3Ks and PI4Ks. Some members of this class contain also an HDAC (histone 
deacetylase) domain. The regulatory subunits of class IA PI3Ks contain a proline-rich region, two SH2 (Src-
homology 2) domains, as well as an iSH2 region (with a coiled-coil structure), which interacts with the catalytic 
subunit. p85! and p85# have at the N-terminus an additional SH3 (Src-homology 3) and BH (BCR homology) 
domain. The structure of p101 and p84/87PIKAP is not well explored. The N-terminus is required for 
association with PI3K", and G#" interaction is mediated by the C-terminal part of these adaptors. The adaptor 
of the class III PI3K Vps34 is the Ser/Thr protein kinase p150 (hVps15). Besides the kinase domain, this protein 
contains HEAT (Huntington, Elongation Factor 3, PR65/A, TOR) domains and a series of WD40 repeats. In the 
case of the PI4K and the PI3K-related proteins, only part of the protein is depicted here, and the number of 
excised amino acids is displayed. ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia-related; DNA-
PKcs, catalytic subunit of DNA-dependent protein kinase; HEAT, Huntington, Elongation Factor 3, PR65/A, 
TOR; iSH2, inter-SH2; mTOR, mammalian target of rapamycin; P, proline-rich region; PX, phox; TRRAP, 
transformation/transcription domain-associated protein. 
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Class III PI3Ks are solely able to phosphorylate PtdIns, and thus generate only PtdIns-3-P. The 
single member of this class is Vps34, of which the S. cerevisiae Vps34p (vacuolar protein sorting 
mutant 34 protein) is the prototype, and has been shown to play an essential role in trafficking of 
newly synthesized proteins from the Golgi to the yeast vacuole, an organelle equivalent to 
lysosomes in mammals.65 In S. cerevisiae, Vps34p forms a complex with the N-terminal 
myristoylated Ser/Thr protein kinase Vps15p, which is required for activation and recruitment of 
Vps34p to Golgi membranes.66 In mammals, Vps34p is associated with the orthologue of yeast 
Vps15p, p150 (also called hVps15), which targets hVps34p to Rab5-positive endosomes. Therefore, it 
appears that hVps34p is also central to endocytosis and vesicular trafficking.67 As it has been 
demonstrated in yeast, Vps34p forms two distinct complexes with Vps15p, Atg6/Vps30p and either 
Atg14 or Vps38.68 Interestingly, deletion of Atg14 leads to defects in autophagy, while deletion of 
Vps38 causes a vacuolar-sorting defect. Mammalian orthologues of Atg14 and Vps38 have not been 
identified yet. The mammalian orthologue of Atg6/Vps30p is Beclin-1, which is capable to bind 
hVps34p directly. Down regulation of Beclin-1 in cells leads to minimal defects in autophagy and 
vesicular trafficking.69 Mice heterozygous for Beclin-1 (Beclin-1+/-) show decreased autophagy and 
enhanced tumor formation.70 In the last years, a lot of attention was given to the requirement of 
Vps34p in the induction of autophagy in nutrient, amino acid, as well as glucose-deprived cells. 
Recent data suggest a role of Vps34p in the activation of mammalian target of rapamycin (mTOR) 
downstream of amino acids, resulting in mTOR-dependent phosphorylation of ribosomal protein S6 
kinase (p70S6K1) and elongation-initiation factor 4E-binding protein (4E-BP1).71 
 
Class IV PI3Ks consists of high molecular weight enzymes with a catalytic core similar to PI3Ks and 
PI4Ks (Fiure 1.6), and include mTOR, DNA-dependent protein kinase (DNA-PKcs), the ataxia 
telangiectasia mutated gene product (ATM), ataxia telangiectasia related (ATR), SMG-1 and 
transformation/transcription domain-associated protein. The first five members are active protein 
serine-threonine kinases that are involved in cell growth control and genome/transcriptome 
surveillance.72,73 DNA-PKcs, ATM, ATR and SMG-1 are involved in DNA-damage responses. The 
first two are primarily responsible for double strand break (DSB) repair, whereas ATR and SMG-1 
respond to ultraviolet-induced stress as well as DSB.74 SMG-1 is involved also in mRNA surveillance 
mechanisms.75 The only active kinase not involved in DNA-damage is mTOR, which is regulated by 
growth factors and nutrient availability, and coordinates protein synthesis, cell growth and 
proliferation.76 
 
1.6.2 PI3K class I activation and signaling 
 
The PI3K pathway is a key signaling transduction cascade controlling the regulation of cell growth, 
proliferation, survival as well as cell migration. PI3Ks are activated by a wide variety of different 
stimuli including growth factors, inflammatory mediators, hormones, neurotransmitters, and 
immunoglobulins and antigens.60,77 The class IA PI3K isoforms PI3K!, # and %, are all bound to one 
of the p85/p55/p50 regulatory subunits, which all harbor two SH2 domains that bind with high 
affinity to phosphorylated Tyr-X-X-Met motifs. These motifs are present in activated growth factor 
receptors, their substrates and numerous adaptor proteins (Figure 1.7). PI3K", the only class IB 
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PI3K, associates with the adaptor proteins p101 or p84/p87PIKAP, and is activated and translocated to 
the plasma membrane by #" subunits of trimeric G proteins (Figure 1.7). Activation of class I PI3Ks 
leads to the production of PtdIns(3,4,5)P3, which recruits adaptor and effector proteins containing 
pleckstrin-homology-(PH)domains, eg, protein kinase B (PKB/Akt). Once at the membrane, 
PKB/Akt is phosphorylated at Thr308 by phosphoinositide-dependent kinase 1 (PDK1). Full 
activation of PKB/Akt is achieved by phosphorylation of Ser473 within the hydrophobic motif by 
socalled PDK2 kinases, of which the mTOR complex 278 and DNA-PKcs79,80 seem to be the most 
relevant ones at present. Once activated, PKB/Akt phosphorylates a plethora of proteins, regulating 
their activity either in a positive or negative manner.78 These target molecules are involved in many 
different cellular outputs, which span from cell cycle progression to cell survival, degranulation, 
metabolism, ribosome biogenesis, translation, transcription, and cell motility (Figure 1.8).81 The 
activation of the PI3K pathway is negatively regulated by the action of two phosphoinositide 
phosphatases. The SH2 domain-containing inositol phosphatase has a 5’-phosphoinositide 
phosphatase activity which converts PtdIns(3,4,5)P3 to PtdIns(3,4)P2.82,83 The other phosphatase is the 
phosphatase and tensin homolog deleted in chromosome ten (PTEN; also MMAC for mutated in 
multiple advanced cancers; or TEP1, TGF-#-regulated and epithelial cell enriched phosphatase 1), 
which hydrolyzes PtdIns(3,4,5)P3 to PtdIns (4,5)P2.84 PTEN is often mutated, deleted or down-
regulated in various tumors, which leads to a constitutive activation of the PI3K pathway.85,86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Simplified activation scheme of class I PI3Ks. Heterodimeric PI3K!, PI3K", and PI3K% complexes 
are activated downstream of growth factors, cytokine receptors and their substrates, whereas PI3K# activation 
is triggered downstream of G protein-coupled receptors (GPCRs). Binding of growth factors to their cognate 
receptor leads to receptor dimerisation and auto-phosphorylation of multiple tyrosines (pY, blue circle), which 
can be located in pYxxM motifs (blue squares). These act as docking sites for the SH2 domains present in the 
PI3K regulatory subunits p85, p55, and p50. This translocates the catalytic PI3K subunit to the plasma 
membrane to initiate the conversion of PtdIns(4,5)P2 to PtdIns(3,4,5)P3. PtdIns(3,4,5)P3 then recruits proteins 
with a pleckstrin homology (PH) domain and amplifies the growth factor signaling cascade. In the case of 
PI3K#, binding of chemokines to GPCRs induces the dissociation of heterotrimeric Gi-proteins. Free G#" 
subunits interact with PI3K# and the adaptor proteins p101 and p84/87PIKAP, usually triggering transient, high 
amplitude signals of PtdIns(3,4,5)P3. 
                                                                                                                                                                  
Introduction - 22  
1.6.3 Cellular functions of AKT 
 
The activated Akt regulates a wide range of target proteins, and has multiple cellular functions 
including cell survival, cell cycle progression, and cell growth. The aberrant activation of Akt 
signaling has been widely implicated in many human cancers. Major functions of the Akt pathway 
involved in human cancers are summarized in Figure 1.8. 
 
Figure 1.8: Schematic signaling of the Akt pathway involved in human cancers. The activation of Akt signaling 
pathway results from various mechanisms, including PI3K activation via receptor tyrosine kinase activation 
and loss of PTEN function. Once activated, Akt regulates a wide range of target proteins and has multiple 
cellular functions including cell survival, cell cycle progression, and cell growth. 
 
1.6.3.1 Cell cycle progression, and Cell Proliferation 
 
PI3K/Akt pathway has been shown to be activated during the G1/S transition and to play a key role 
in cell cycle progression.87 Akt phosphorylates many kinds of proteins involved in protein synthesis 
and cell cycle regulation. These proteins include glycogen synthase kinase-3! (GSK3!), the forkhead 
transcription factors, cyclindependent kinase inhibitors p21WAF1 and p27KIP1 and mTOR.88 GSK3! 
phosphorylates cyclin D1 and c-Myc, which play distinct roles in cell cycle progression through G1 
phase,89 and promotes their degradation.90,91 Akt phosphorylates and inhibits GSK3!, thereby 
contributing to the stabilization of cyclin D1 and c-Myc. The forkhhead transcription factors repress 
cyclin D1 expression while enhancing expression of the cell cycle inhibitors p27KIP1 and p130Rb2.92 
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Akt phosphorylates the forkhead transcription factors, then promotes the cyclin D1 expression and 
inhibits the expression of p27KIP1 and p130Rb2. Recent studies suggest that Akt also regulates p27KIP1 
stability,93,94 possibly through an upregulation of Skp2.95,96 Akt also directly phosphorylate 
p21WAF197,98 and p27KIP1,93,99 thus leading to their cytoplasmic mislocalization and cell cycle 
progression. p53 is probably the best characterized tumor suppressor, which regulates cell cycle and 
apoptosis.100 Akt can promote p53 degradation by phosphorylating and activating its negative 
regulator Mdm2.101,102 
 
1.6.3.2 Cell survival and apoptosis 
 
The activation of the PI3K/PKB pathway has an antiapoptotic effect. Here, PKB/Akt 
phosphorylates and inhibits caspase 9, a protease crucial in the initiation of the apoptotic cascade.103 
PKB/Akt also phosphorylates the death promoter BAD at Ser136, and thus releases the anti-
apoptotic proteins Bcl-2 and Bcl-XL.104 PKB/Akt can also activate and phosphorylate I-kB kinase. 
This kinase in turn phosphorylates and inactivates the inhibitor I-kB, which then releases the 
transcription factor NF-kB. As a consequence, the latter translocates to the nucleus and activates 
transcription of anti-apoptotic proteins such as Bcl-2 and Bcl-XL.105 Finally, inactivation and 
cytosolic retention of FOXO as mentioned above, leads to a block in transcription of FasL, and thus 
intercepts ligand-induced apoptosis. 
 
1.6.3.3 Cell growth, transcription, and translation 
 
mTOR participates in the regulation of the initiation of mRNA transcription and protein translation 
in response to the nutrient availability and growth factor stimuli.106 mTOR is phosphorylated and 
activated downstream of PI3K/Akt, and plays an important role in stimulating cell proliferation.107 
mTOR controls cell growth by activating p70S6K and inhibiting 4E-BP1, two events which stimulate 
protein translation.107 The PI3K/Akt pathway has recently been shown to activate mTOR, at least in 
part, through the pathway involving Akt’s phosphorylation and inhibition of the tuberous sclerosis 
complex-2 (TSC2) gene product tuberin.108-110 TSC2 is one of the two genes found mutated in the 
tuberous sclerosis complex disease. The other one is TSC1, which encodes the protein hamartin, an 
obligatory binding partner of tuberin. Hamartin/tuberin complex inhibits p70S6K and activates 4E-
BP1. Akt directly phosphorylates tuberin and inhibits the formation of this complex. mTOR exists in 
mutually exclusive complexes with raptor (regulatory-associated protein of TOR) or rictor 
(rapamycin-insensitive companion of TOR).111,112 Recent studies have shown that mTOR is not only a 
major downstream target of Akt but also a critical activator of Akt by forming complex with rictor.112 
Importantly, the raptor-mTOR complex is rapamycin sensitive and is responsible for 
phosphorylation of p70S6K and 4E-BP1, whereas the rictor-mTOR complex is rapamycin insensitive 
and is one of the enzymes that can catalyze the activating phosphorylation of Akt at Ser473 and 
facilitate Thr308  phosphorylation by PDK1 (Figure 1.9). 
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Figure 1.9: Schematic diagram of feedback regulation of Akt by rictor-mTOR. 
 
1.6.3.4 Angiogenesis 
 
The activation of the Akt signaling pathway appears to play an important role in the angiogenesis. 
Akt, activated in response to proangiogenic factors such as vascular endothelial growth factor 
(VEGF), prevents endothelial cell apoptosis.113 Akt also phosphorylates and activates endothelial 
nitric oxide synthase and allows for neovascularization and VEGF-mediated cell migration.114 
Forced expression of Akt induces angiogenesis,115 suggesting the direct and sufficient role of Akt in 
regulating angiogenesis. Hypoxia inducible factor-1! (HIF-1!) is activated by hypoxia and induces 
the transcription of various genes involved in angiogenesis, including VEGF.116 Increase of PI3K and 
Akt or decrease of PTEN activity induces HIF-1! expression in cancer cells, leading to upregulation 
of VEGF and angiogenesis.117 Recently, an increased PI3K activity and Akt1 phosphorylation has 
been shown to be required for the HIF-1! expression in invasive breast carcinoma.118 In addition, a 
recent study showed that Akt can induce the HIF-1! expression independent of hypoxia.119 
 
1.6.4 ACTIVATION OF AKT IN HUMAN CANCER 
 
In addition to preclinical studies, many clinical observations support targeting the PI3K/Akt/ 
mTOR pathway in human cancer. The frequent activation of Akt has been reported in many human 
cancers, including carcinomas of breast, prostate, gastric, lung, ovary, pancreas, and thyroid, as well 
as in glioblastoma and various hematological malignancies.120 Numerous studies have shown the 
associations between Akt activation and the clinicopathological characteristics, such as advanced 
stage, poor prognosis and histological grade.120 Akt activation in human cancer is caused by various 
mechanisms which are described below. 
 
1.6.4.1 Alterations Related to AKT Activation in Human Cancer 
 
Alterations of PI3K 
The gene PIK3CA, which encodes the p110! catalytic subunit of PI3K, is frequently amplified in 
some human cancers. In ovarian cancer, an increased copy number of PIK3CA has been shown in 
approximately 40% cases with increased PI3K activity.121 Increased PIK3CA gene copy number was 
also reported in primary gastric carcinomas,122 head and neck squamous cell carcinomas,123 uterine 
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cervical carcinoma.124 Similar to ovarian cancer cell lines, PIK3CA gene amplification in gastric cell 
lines has been shown to be strongly associated with the increased expression of PIK3CA and an 
elevated Akt activity.122 Somatic mutations of the PIK3CA gene have been reported in gastric, 
colorectal, breast, and endometrial carcinomas and certain brain tumors.72,125 A mutation of the 
PIK3R1 gene, which encodes the p85! regulatory subunit of PI3K, has been shown in human T-cell 
lymphoma cell line from a patient with Hodgkin’s disease.126 The mutant protein contributes to a 
constitutively active form of PI3K. Compared to PIK3CA, mutation of the PIK3R1 gene is an 
infrequent event in human cancer. 
 
Alterations of PTEN 
PTEN is a tumor suppressor, which negatively regulates Akt pathway. Loss of PTEN function leads 
to an elevated concentration of the PIP3 substrate, and consequent constitutive activation of 
downstream components of the PI3K pathway, including the Akt and mTOR.84 The loss of the PTEN 
function via gene mutation, deletion, or promoter methylation has been reported in some types of 
tumors, including endometrial carcinoma, glioblastoma multiforme, anaplastic astrocytoma, 
prostate, ovarian and thyroid carcinoma, and hepatocellular carcinoma, breast, lung, renal cell 
carcinoma and melanoma, microsatellite-high colorectal carcinoma and gastric carcinoma.127 
Decreased expression of PTEN has been reported to be associated with lymph node metastasis and 
poor prognosis and to be predictive of the failure of tamoxifen treatment.128 We recently reported 
that loss of heterozigosity at the PTEN gene locus was associated with Akt activation and resulted in 
chemoresistance in gastric carcinomas129 and associated with negative progesterone receptor 
expression in breast carcinomas.130 
 
Alterations of Akt 
Akt2 gene amplification is considered to be a frequent event in various human cancers. Akt2 gene 
amplifications have been reported in ovarian, pancreatic, breast, and gastric cancer and head and 
neck squamous cell carcinomas.123,131,132 In contrast to Akt2, Akt1 gene amplification is not a frequent 
event in any tumor types. Recently, Akt1 gene amplification with Akt1 overexpression has been 
reported in a single case of gliosarcoma.133 Although Akt1 gene amplification is a rare event, Akt1 
overexpression has been reported in breast and colorectal cancers.134,135 Akt3 gene amplification has 
not been reported so far. 
 
1.6.5 PI3K/Akt/mTOR PATHWAY AND CHEMOTHERAPEUTIC RESISTENCE  
 
The rationale for targeting the PI3K/Akt/mTOR pathway in combination therapy comes from data 
describing constitutive or residual pathway activation in cells that have developed resistance to 
conventional chemotherapy and radiation,136 as well as to other targeted therapies such as EGFR 
antagonism. In these cases, combining chemotherapy or radiation with a pathway inhibitor can 
overcome acquired resistance to EGFR tyrosine kinase inhibitors. Some standard chemotherapeutic 
agents appear to directly inhibit Akt in vitro, and the cytotoxicity may be a direct consequence of 
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inhibition of Akt signaling.137,138 Because Akt is integrally involved in cellular survival, many groups 
have investigated the effects of combining chemotherapy with pathway inhibitors. 
 
1.6.6 THERAPEUTIC APPROACHES OF TARGETING THE AKT PATHWAY 
IN CANCER 
 
The PI3K/Akt signaling pathway has become an attractive target for cancer drug development for 
some reason. As abovementioned, this pathway inhibits many proteins that are related to apoptosis 
and which regulate cell cycle progression and promote cell proliferation and growth. It is expected 
that inhibition of this pathway might therefore inhibit cell growth and proliferation, and reverse the 
repression of apoptosis and resistance to cytotoxic agents in cancer cells. In addition, many 
components of the PI3K/Akt pathway are kinases which are ideal for the development of small 
molecule inhibitors. Moreover, the hyperactivation of the PI3K/Akt pathway is found in a wide 
range of tumors and numerous studies have shown that drugs inhibiting this pathway are likely to 
be used for treating various types of cancer. However, based on the complexity of the PI3K/Akt 
signaling and crosstalk with multiple pathways, combined with its importance in multiple 
physiological functions, it is very important to confirm efficacy and safety in the development of the 
target therapies for this pathway (Figure 1.10). A number of inhibitors of proteins involved in 
PI3K/Akt signaling pathway have been under development, and some agents have now entered 
clinical trials or been approved for clinical practice. These agents include inhibitors, which directly 
inhibit the PI3K/Akt/mTOR pathway and indirectly inhibit this pathway by inhibiting the 
upstream regulators of PI3K/Akt, such as membrane growth factor receptors. Ongoing clinical trials 
are expected to show the efficacy of these agents while also revealing the mechanisms of sensitivity 
or resistance to those agents by accompanying translational research. 
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Figure 1.10: PI3K-Akt-mTOR pathway and cross-talk with other signaling cascades: (Ras/Raf/MAPK and BCR-
ABL). PI3K-Akt and Ras/Raf/MAPK pathways are common routes that control key cellular responses. The 
large amount of cross-talk between these pathways is often responsible for treatment resistance. 
 
1.6.6.1 Akt inhibitors 
 
As we described above, PI3K/Akt/mTOR pathway plays a critical role in proliferation and survival 
in tumor cells and is also linked with resistance to radiotherapy, chemotherapy, endocrine therapy 
and novel anticancer therapies.139 In this setting, this pathway seems to bring together all the 
characteristics of a good target for the treatment of cancer. Currently, clinical trials with inhibitors of 
the PI3K/Akt pathway in monotherapy or in combination with other anti cancer drugs are 
underway in cancer patients. In addition, these novel inhibitors are being also tested in chemo- and 
hormonal-therapy refractory patients.140,141 Although we will focus on inhibitors of Akt, currently 
PI3K and mTOR inhibitors are more advanced in their development than Akt inhibitors. During 
recent years, intense efforts made in the search for Akt inhibitors have yielded several promising 
candidates, such as lipid-based inhibitors that compete with PIP3 to bind the PH domain of Akt, 
ATP-competitive inhibitors, small molecule inhibitors, and peptide-based inhibitors reviewed 
elsewhere.142 The lipid-based inhibitors include perifosine, an orally active membrane-permeable 
ether lipid with a single long alkyl chain (Figure 1.11).  
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Figure 1.11: Compound structure for Perifosine. 
 
In vitro, perifosine inhibits translocation of Akt to the cell membrane, and inhibits the growth of 
melanoma, lung, prostate, colon, and breast cancer cells in association with inhibition of Akt 
activity.143,144 Additional in vitro data demonstrates synergistic effects of perifosine and traditional 
chemotherapeutic agents such as etoposide in leukemia cells,145 doxorubicin in multiple myeloma 
cells,146 and temozolomide in glioma cells.147 Perifosine has also been found to sensitize cancer cells 
to apoptosis and cell cycle arrest induced by radiation in vitro and in vivo.148,149 Perifosine has also 
shown efficacy and tolerability in phase I clinical trials.150 However, given the limited efficacy of 
perifosine monotherapy in a variety of solid malignancies in phase II trials, an alternative strategy 
would be to combine perifosine with chemotherapy, radiation therapy and targeted agents in an 
attempt to enhance cytotoxicity and overcome chemotherapeutic resistance through inhibition of the 
Akt pathway. These data have prompted several phase I combination studies with perifosine 
including evaluation of perifosine combined with lenalidomide,151 sorafenib, sunitinib, docetaxel, 
paclitaxel, imatinib, or gemcitabine. In addition, a phase I trial combining perifosine and 
radiotherapy in advanced solid tumors demonstrated that perifosine could be safely utilized as a 
radiation sensitizer, and phase II trials with this strategy are in development.152  
 
1.6.6.2 Combining pathway inhibitors with other targeted therapies 
 
The concept of “oncogene addiction” asserts that some cancers depend on one gene or a few genes 
for their survival and maintenance of the malignant phenotype. Although PI3K/Akt/mTOR 
pathway activation is required for the development and/or maintenance of certain stages of cancer, 
tumor heterogeneity and clinical experience suggest that combination therapy will be required to 
achieve remission or cure in most patients. Because signaling of multiple receptor tyrosine kinases 
(RTKs) is propagated through Akt, simultaneous inhibition of RTKs such as IGF-IR or erbB family 
members with pathway components such as Akt or mTOR may circumvent feedback activation seen 
with either approach alone. Such an approach can be considered proximal and distal signaling 
inhibition (Figure 1.12, left panel). Based on the observed feedback activation of Akt by mTOR 
inhibitors, it is possible that they might be most effective when combined with proximal pathway 
inhibitors. For example, synergistic effects between rapamycin and LY294002, an upstream inhibitor 
of PI3K, are commonly observed in vitro.153-155 Most recently, Fan et al showed that a dual inhibitor 
of PI3K! and mTOR, PI-103, was able to inhibit Akt activity as well as proliferation in glioma cells, 
regardless of PTEN or EGFR status.156 PI-103 was effective in inhibiting the growth of glioma 
xenografts in the absence of toxicity, most likely through a cytostatic mechanism.  
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Another possible approach is to combine inhibition of the PI3K/Akt/mTOR pathway with 
inhibition of a parallel pro-survival signaling pathway such as the MEK/ERK pathway (Figure 1.12, 
middle panel).157 This approach abrogates compensatory activation of other pro-survival pathways 
when the PI3K/Akt/mTOR pathway is inhibited. For example, combining an inhibitor of PI3K with 
an inhibitor of MEK causes a synergistic increase in apoptosis in both PTEN mutant and wild-type 
cells.158  
 
In addition to combining PI3K/Akt/mTOR inhibitors with agents that inhibit either the same or 
parallel pro-survival signaling pathways, PI3K/Akt/mTOR inhibitors have also been combined 
with targeted agents that defy easy categorization such as imatinib and those that do not directly 
affecting signaling pathways, eg, histone deacetylase (HDAC) inhibitors and proteasome inhibitors 
(Figure 1.12, right panel).159 Although the mechanisms behind the efficacy of these combinations are 
not completely understood, they represent potentially useful combinations for patients whose 
tumors do not respond to more conventional therapy regimens. 
 
Figure 1.12: Combinatorial approaches with inhibitors of the PI3K/Akt/mTOR pathway. Several approaches 
can be employed when combining pathway inhibitors with other targeted therapies. Inhibition of proximal 
pathway components, such as RTKs and oncogenes, combined with distal inhibition of Akt or mTOR may be 
an effective approach to circumvent feedback activation that could occur with distal inhibition alone (left 
panel). Alternatively, dual inhibition of parallel signaling pathways prevents compensatory activation of 
redundant pro-survival pathways (middle panel). Finally, pathway inhibition can be combined with several 
other types of targeted therapies, including inhibition of HDAC complexes, the proteasome and 
cyclooxygenase-2 (COX-2) (right panel). 
 
1.7 THE MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY 
 
Human tumorigenesis is a multistep process during which accumulation of genetic and epigenetic 
alterations leads to the progressive transformation of a normal cell into a malignant cancer cell. 
During this process, cancer cells acquire new capabilities (hallmarks) that enable them to escape 
from normal homeostatic regulatory defense mechanisms. These hallmarks are defined as: self-
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sufficiency in growth signals, insensitivity to antiproliferative signals, evasion from apoptosis, 
limitless replicative potential, sustained angiogenesis, and increased motility and invasiveness.160 
While the mechanisms by which cancer cells acquire these capabilities vary considerably between 
tumors of different types, most if not all of these physiological changes involve alteration of signal 
transduction pathways. Among the signaling pathways most frequently dysregulated in human 
cancer is the Ras-Raf-MEK-ERK1/2 pathway. The Ras-dependent ERK1/2 MAPK pathway is one of 
the best-studied signal transduction pathways. Mammalian cells possess four well characterized and 
widely studied MAPKs (Figure 1.13). These cascades are comprised of three protein kinases that act 
as a signaling relay controlled, in part, by protein phosphorylation: a MAPK kinase kinase 
(MAPKKK), a MAPK kinase (MAPKK) and a MAPK.161 The terminal serine/threonine kinases 
(MAPKs) are the ERK1/2, the c-Jun amino-terminal kinases (JNK12/3; also called SAPKs), p38 
kinases (p38!/#/"/%) and ERK5. Generally, the ERK pathway is activated by growth factor-
stimulated cell surface receptors, whereas the JNK, p38 and ERK5 pathways are activated by stress 
and growth factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Mammalian MAPK cacades. There are four major mammalian MAPKKK–MAPKK–MAPK protein 
kinase cascades. Many of the substrates for MAPKs are nuclear transcription factors. Interactions and substrates 
were compiled from information from STKE (http://stke.sciencemag.org/index.dtl). 
 
ERK1/2 MAP kinases are activated by virtually all growth factors and cytokines acting through 
receptor tyrosine kinases, cytokine receptors or G protein-coupled receptors (Figure 1.14). Typically, 
ligand binding to receptor tyrosine kinases induces dimerization of the receptor and 
autophosphorylation of specific tyrosine residues in the C-terminal region. This generates binding 
sites for adaptor proteins, such as growth factor receptor-bound protein 2 (GRB2), which recruit the 
guanine nucleotide exchange factor Sos at the plasma membrane. Sos activates the membrane-
bound Ras by catalyzing the replacement of GDP with GTP. In its GTP-bound form, Ras recruits Raf 
kinases (ARAF, BRAF and CRAF) to the plasma membrane, where they become activated by a 
complex interplay of phosphorylation events and protein-protein interactions. Raf acts as a 
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MAPKKK and activates the MAPKKs MEK1 and MEK2, which, in turn, catalyze the activation of 
the effector MAP kinases ERK1 and ERK2.162 Once activated, ERK1/ERK2 phosphorylate a panoply 
of nuclear and cytoplasmic substrates involved in diverse cellular responses, such as cell 
proliferation, survival, differentiation, motility, and angiogenesis.163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: Schematic representation of the Ras-Raf-MEK-ERK1/2 MAP kinase pathway. The figure shows the 
cascade of activation of the MAP kinases ERK1/ERK2 mediated by growth factor binding to receptor tyrosine 
kinases. See text for details. GF, growth factor; RTK, receptor tyrosine kinase. 
 
1.7.1 The ERK1/2 MAP kinase pathway is a key regulator of cell proliferation and 
survival 
 
Multiple lines of evidence have implicated the ERK1/2 MAP kinase pathway in the control of cell 
proliferation.164 ERK1 and ERK2 are activated in response to virtually all mitogenic factors. Several 
studies have reported that the mitogenic response to growth factors is correlated with their ability to 
induce sustained ERK1/2 activity.165 These early findings were confirmed by subsequent RNA 
interference-based studies showing that silencing of ERK1/ERK2 expression inhibits the 
proliferation of various cell types.166,167 Treatment with small molecule inhibitors of MEK1/MEK2 
was reported to inhibit the proliferation of a variety of cell types.168 Reciprocally, expression of 
constitutively-active forms of MEK1 was sufficient to stimulate cell proliferation and relax growth 
factor dependency.169 ERK1/2 signaling is required for the progression of cells from the G0/G1 to S 
phase.164,170 Activation of the ERK1/2 pathway is associated with induction of the positive cell cycle 
regulators cyclin D1171 and c-Myc,172 and with down-regulation of anti-proliferative proteins such as 
Tob1,173 Foxo3a174 and p21.175 In addition to its direct role in the cell division cycle, the ERK1/2 MAP 
kinase pathway also regulates cell growth by stimulating protein and nucleotide biosynthesis.176 
One mechanism by which the ERK1/2 pathway increases global protein translation is through 
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phosphorylation and inactivation of tuberin (also known as TSC2), a negative regulator of mTOR, 
resulting in increased mTOR signaling.177 Studies in several experimental systems have highlighted 
the important role of the Raf-MEK-ERK1/2 MAP kinase pathway in the control of cell survival.178,179 
Early studies have shown that activation of the ERK1/2 pathway prevents apoptosis induced by 
growth factor withdrawal, loss of matrix attachment or cytoskeletal disruption in cultured cells.180,181 
These findings were reinforced by genetic studies showing that loss of ERK1/ERK2 or 
MEK1/MEK2 induces cell death in various mouse tissues.182 ERK1/2 signaling promotes cell 
survival by repressing the expression or activity of pro-apoptotic Bcl-2 family proteins, such as Bim 
and Bad, and by inducing the expression of prosurvival members like Bcl-2 and Mcl-1.179 
 
1.7.2 Hyperactivation of the ERK1/2 MAP kinase pathway in cancer 
 
Given the central role of the Raf-MEK-ERK1/2 signaling pathway in cell proliferation and survival 
signaling, it is therefore not surprising that alterations in this pathway are highly prevalent in 
human cancer. Multiple genetic changes can lead to hyperactivation of the ERK1/2 pathway in 
cancer. Aberrant activation of receptor tyrosine kinases such as the epidermal growth factor (EGF) 
receptor, as a result of gene amplification or gain of function mutations, is frequently observed in 
carcinomas and brain tumors.183 Activating mutations in RAS genes, most often in KRAS, are found 
in ~30% of cancers and are generally acquired early in the tumorigenic process.184 More recently, 
large-scale resequencing studies have revealed that BRAF is mutated in ~20% of all cancers and in 
more than 40% of melanomas.185 The majority of these mutations are clustered in the kinase domain 
of B-Raf and lead to the stimulation of ERK1/2 activity in cells.186 It is noteworthy that RAS and 
BRAF mutations are generally mutually exclusive in tumors, suggesting an epistatic relationship. 
Also, activating mutations in MEK1 gene are found at low prevalence in lung carcinomas, 
melanomas and colon carcinomas.187,188 However, no mutation in the ERK1 or ERK2 gene has been 
reported to date in tumors. Consistent with these observations, numerous studies using clinical 
specimens have documented the hyperactivation of MEK1/MEK2 and ERK1/ERK2 in solid tumor 
and hematological malignancies.189,190 Preclinical pharmacological studies have demonstrated that 
blockade of the ERK1/2 pathway with small-molecule MEK1/2 inhibitors markedly restrains the 
proliferation of various carcinoma and leukemic cell lines by inducing cell cycle arrest and 
apoptosis.191 In vivo studies further established that administration of orally available MEK1/2 
inhibitors elicits significant tumor regression in mouse xenograft models.192 The strategic position of 
MEK1 and MEK2 in the Ras-dependent ERK1/2 pathway in conjunction with a promising 
preclinical profile have provided strong rationale for the development of small molecule inhibitors 
of MEK1/2 for chemotherapeutic intervention in cancer.190 
 
1.7.3 Raf inhibitors 
 
Therapeutic strategies that target Raf seem ideally suited to address the high percentage of human 
cancers displaying constitutive activation of the MAP kinase pathway. Therapeutic approaches 
include inhibitors of chaperone proteins, eg, Hsp90, which act to indirectly inhibit Raf by 
destabilization of the protein leading subsequently to its degradation. The impressive efficacy of 
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geldanamycin analogs, which are naturally occurring antibiotics, is well documented but likely 
results from their broader pleiotropic effects.193 Few small-molecule Raf kinase inhibitors have been 
reported. Both L-779450 and SB203580 have been shown to be more effective at inhibiting c-Raf than 
B-Raf.194,195 
 
To date, the most successful anti-Raf inhibitor has been sorafenib (BAY 43-9006; Nexavar), an orally 
available compound that received FDA approval in 2005 for the use in advanced renal cell 
carcinoma (RCC). Sorafenib is a bi-aryl urea compound196 that was originally developed as an 
inhibitor of Raf-1.197 Subsequent analysis revealed that sorafenib was a potent inhibitor of both wild-
type and mutant (eg, V600E, the most frequent mutation found in human cancers) B-Raf kinases in 
vitro. Crystallographic analyses of sorafenib complexed with the kinase domain of B-Raf showed 
that the inhibitor bound to the ATP-binding pocket and prevented kinase activation, thus 
preventing substrate binding and phosphorylation (Figure 1.15).198 Shortly after clinical analyses 
begin, it was revealed that sorafenib also showed very potent activity for other protein kinases in 
vitro  and in vivo, in particular, for the proangiogenic RTKs such as VEGFR-2, VEGFR-3, PDGFR-#, 
Flt-3, c-Kit and FGFR-1.199 In cell culture and mouse models representing a wide range of tumor cell 
types, sorafenib exhibited broad antitumor activity and was associated with reduced MEK and ERK 
activation, supporting the possibility that its antitumor activity involves, in part, inhibition of Raf.199 
However, despite its association with reduced ERK activation, sorafenib antitumor activity must 
also be a consequence of its ability to inhibit angiogenesis-related kinases as well as other non-Raf 
kinases. This possibility is supported by the potent antitumor activity that was independent of Ras 
or B-Raf mutation status that was seen with sorafenib in xenograft studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Ribbon diagram of the B-Raf kinase domain bound to BAY43-9006. The amino terminus lobe is 
composed primarily of anti-parallel #-strands, including the phosphate binding loop (P-loop) responsible for 
functional binding of ATP. The kinase activation segment contains the Raf family conserved phosphorylation 
sites, T491 and S494. In this crystal structure, the Raf activation segment is disordered and indicated here with a 
dotted line. The carboxyl-terminal lobe is primarily composed of !-helices. The !-helix E (!E helix) functions to 
position the C-terminal catalytic residues in the proper orientation for the binding of MEK substrate and the 
phosphotransfer reaction. The Raf inhibitor BAY43-9006 is shown here binding in the kinase active site located 
between the two lobes. 
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Phase I clinical trials established sorafenib as a safe and well-tolerated oral agent with skin rash and 
diarrhea as the most common adverse effects.200 Results from phase I clinical trials suggested clinical 
activity in several patients with RCC, resulting in subsequent clinical trials focused on RCC. In 
addition, several single agent and combination clinical studies are ongoing in hepatocelluar 
carcinoma, non-small-cell lung cancer, prostate cancer, breast cancer, ovarian cancer, pancreatic 
cancer, melanoma and hematological malignancies.201 The results of clinical trial analyses of 
sorafenib have not provided sufficient information to conclude that inhibition of Raf provides a 
clinical value. Although preclinical cell culture and mouse model analyses showed that continued 
expression of mutant B-Raf is critical for melanoma growth and tumorigenicity, phase II clinical trial 
analyses with sorafenib observed little or no antitumor activity when evaluated as monotherapy for 
advanced melanomas.202 Some clinical efficacy had been seen for melanomas when sorafenib was 
used in combination, with clinical trials ongoing for advanced melanomas with sorafenib 
combination with bevacizumab or carboplatin and paclitaxel. The clinical success of sorafenib  has 
prompted a debate regarding the advantages and disadvantages of highly specific versus broad 
specificity inhibitors.203 As cancer is a multistep process, requiring multiple alterations, it is expected 
that effective cancer treatment requires concurrent activities that target different defects.160 The 
greater success of combination chemotherapy is consistent with this premise. The ability to optimize 
the pharmacokinetics and pharmacodynamic properties of a single agent with multiple activities is 
also a great advantage for the successful clinical development of a drug. In the development of 
sorafenib, the intention was the identification of a Raf inhibitor, with the activity against other 
protein kinases fortuitous and unplanned. Hence, this has complicated a full understanding of the 
mechanism of action of sorafenib and the importance of its anti-Raf activities for its clinical efficacy. 
Therefore, whether blocking Raf will be a clinically effective approach will require future clinical 
evaluation of more specific and potent Raf kinase inhibitors. The clinical success of highly selective 
protein kinase inhibitors, in particular monoclonal  antibody (mAb)-based drugs (eg, trastuzumab, 
bevacizumab), demonstrates that there is clinical value for both highly selective and multitargeted 
inhibitors. 
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A significant proportion of Hodgkin lymphoma (HL) patients refractory to first-line chemotherapy 
or relapsing after autologous transplantation are not cured with currently available therapies. 
Phosphoinositide 3-Kinase/Akt (PI3K/Akt) and mitogen activated protein kinase (MAPK) signaling 
pathways regulate many cellular processes, and dysregulation of these signaling cascades is often 
found in HL. These pathways can be targeted using the AKT inhibitor perifosine (Æterna Zentaris 
GmBH, Germany, EU), and the RAF/MEK/ERK inhibitor sorafenib (Nexavar, Bayer, Germany, 
EU). 
 
We hypothesized that perifosine in combination with sorafenib might have a therapeutic activity in 
HL. The proposed project was aimed at investigating in vitro and in vivo the activity and 
mechanism(s) of action of perifosine in combination with sorafenib by using three HL cell lines (HD-
MyZ, L-540, HDLM-2). 
 
• The effects of perifosine and sorafenib on cell growth and survival, used as single agents or 
in combination, were evaluated in vitro in HL cell lines. Tumor cells were exposed to 
increasing concentrations of each agent and the combined treatment. At the end of the 
incubation, viable cell countings and apoptosis assays were carried out. To investigate the 
mechanism(s) of action of perifosine/sorafenib, Western blot, mitochondrial depolarization, 
protein arrays, cell cycle and gene expression profiling analysis were assessed. 
 
• Additionally, the antitumor efficacy and mechanism(s) of action of perifosine/sorafenib 
were investigated in vivo in nonobese diabetic/severe combined immunodeficient 
(NOD/SCID) mice. The antitumor activity were evaluated by comparing the survival 
(Logrank test) of treated mice with those of mice treated with the drug solvent. 
Furthermore, tumor-bearing NOD/SCID mice were treated with perifosine and sorafenib 
alone or in combination. Subsequently, tumor nodules were excised and tumor cells were 
analyzed by means of the appropriate immunohistochemical procedures. Apoptosis and 
necrosis were evaluated by the TdT-mediated dUTP nick and labeling (TUNEL) staining 
method. Image analysis were carried out using the open source ImageJ software. 
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3.1 REAGENTS 
 
Sorafenib (BAY43-9006) was purchased from Bayer Schering Pharma (Berlin, &Germany, EU). 
Perifosine was obtained from Aeterna Zentaris (Frankfurt, Germany, EU). The pan-caspase inhibitor 
Z-VADfmk was purchased from R&D Systems (Minneapolis, USA). Tetramethylrhodamine ethyl 
ester (TMRE) were purchased from Invitrogen (Milan, Italy, EU). All reagents were formulated as 
recommended by their suppliers.  
 
3.2 CELL LINES 
 
HD-MyZ, HDLM-2 and L-540 HL cell lines were purchased from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany, EU). Cell lines were cultured 
in RPMI-1640 (Lonza, Basel, Switzerland) supplemented with 10-20% (v/v) inactivated fetal bovine 
serum (FBS) (Lonza), 1% (v/v) L-glutamine (Lonza) in a humidified chamber (95% air, 5% CO2) at 
37°C. All cell lines were regularly screened to ensure absence of mycoplasma contamination by 
MycoAlert® Mycoplasma Detection Kit (Lonza), according to the manufacturer’s instructions. 
 
3.3 EXPERIMENTAL FORMAT 
 
The proposed project is aimed at investigating in preclinical models, in vitro and in vivo, the anti-
lymphoma activity of combination of perifosine and sorafenib. This is expected to provide a clear 
rationale to early-phase clinical trials using lymphoma-eradicating combinations of targeted agents. 
The aim of the project was pursued through the following phases: 
 
• Phase 1 - In vitro anti-lymphoma effects and mechanism(s) of action of perifosine and 
sorafenib used as single agent or in combination. Three HL cell lines (HD-MyZ, HDLM-2 
and L-540) were used to investigate the effects of perifosine and/or sorafenib on cell growth 
and survival. Firstly, tumor cells were exposed to increasing concentrations of each agent (0 
– 10 µM) for dose-response assay, secondly HD-MyZ cell line was exposed to (2.5 µM) 
perifosine and/or (2.5 µM) sorafenib, whereas L-540 and HDLM-2 cell lines were treated 
with (5 µM) perifosine and/or (5 µM) sorafenib for proliferation and viability assays. To 
perform the different experiments, an appropriate number of cells according to the type of 
experiments were seeded in culture plates or flask (Costar, Corning Incorporated, NY, 
USA). Next day, drugs were added every 24 hours to the media at the concentrations 
indicated in each experiment. HD-MyZ and HDLM-2 cells were simultaneously treated 
with the indicated drug concentrations; L-540 cells were sequentially treated with perifosine 
for 24 hours followed by sorafenib for an additional 24 and 48 hours. At the end of the 
incubation, viable cell countings and apoptosis assays were carried out. To investigate the 
mechanism(s) of action of targeted agents, cell cycle analysis, caspase activation assays, 
mitochondrial membrane depolarization ('(m), Western blot analysis, protein arrays, and 
gene expression profiling were used.  
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• Phase 2 - In vivo anti-lymphoma activity of perifosine in combination with sorafenib. For 
testing the antitumor activity of the compounds, the best route of administration and the 
maximal tolerated doses of the compounds as single agents and in combination, were first 
chosen. The compounds were administered, according to the selected doses and schedules, 
to mice with advanced lymphomas (start of treatment when subcutaneous (SC) tumors were 
palpable or a 3 days after IV tumor injection). The antitumor activity was evaluated by 
comparing the weight of tumors (Student’s t test) and the survival (logrank test) of treated 
mice with those of mice treated with the drug solvent. Five mice per group were treated and 
each experiment was performed at least twice.  
• Phase 3 - In vivo anti-lymphoma mechanism(s) of action perifosine/sorafenib. Tumor-
bearing NOD/SCID mice were treated with the appropriate combination of targeted agents 
as established in Phase 2. Subsequently, 5 days following treatment, tumor nodules were 
excised and tumor cells were analyzed by means of the appropriate immunohistochemical 
procedures. Apoptosis and necrosis were evaluated by the TdT-mediated dUTP nick end 
labeling (TUNEL) staining method. Images of tissue sections were acquired at 2 – 20x 
magnification with an automatic high-resolution scanner (dotSlide System, Olympus, Tokio, 
Japan) and subdivided in a collection of non-overlapping RGB images in TIFF format. Image 
analysis will be carried out using the open source ImageJ software (Rasband, W.S., ImageJ, 
U.S. National Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/). 
 
3.4 PROLIFERATION AND VIABILITY ASSAYS 
3.4.1 Viable cell counting 
 
HD-MyZ, L-540 e HDLM-2 cell lines (0.2 – 0.4 × 106/mL) resuspended in FBS-supplemented culture 
medium were exposed to perifosine, sorafenib or control vehicle for 48 – 72 hours. At the end of 
incubation, viable and dead cells were identified by Annexin-V/Propidium Iodide (PI) staining and 
flow cytometry analysis. To obtain absolute cell counts, cell samples were supplemented with Flow-
Count beads (Beckman Coulter, Milan, Italy, EU) and stained with PI. Cell counts per µl were 
calculated by the following equation: viable cells (Annexin-V-/PI-) × total beads/counted beads.   
 
3.4.2 Assesment of apoptosis 
 
The Annexin-V–fluorescein isothiocyanate (FITC) assay (Immunostep, Salamanca, SP, EU) was used 
to detect cell death by apoptosis or necrosis after 48 – 72 hours exposure to perifosine and 
sorafefenib used as single agent or in combination. Briefly, cells were washed twice with cold 
phosphate-buffered saline (PBS) (BioWhittaker, Lonza, Verviers, Belgio, EU), resuspended in 
binding buffer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl2, pH 7.4), and incubated with Annexin-V–
FITC. At the end of the incubation, PI was added. Samples were acquired by setting photomultiplier 
tubes on the autofluorescence of the related negative control. All plots were gated on high Forward 
Scatter (FSC) and low Side Scatter (SSC) to exclude cell debris. A minimum of 50,000-gated events 
was collected per sample. Data were acquired on a BD fluorescence-activated cell sorting 
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(FACS)Calibur using BD CellQuest software version 3.3 (Becton Dickinson, Lincoln Park, NJ) and 
analyszed by FlowJo 8.7.1 software version for Macintosh (Tree Star, Inc. Ashland,OR). Annexin-
V/PI double staining allows quantification of early (Annexin-V+/PI-) and late (Annexin-V+/PI+) 
apoptotic cells, as well as necrotic cells (Annexin-V-/PI+).  
 
3.4.3 Cell cycle analysis 
 
Cell cycle distribution was analyzed by DNA staining with the fluorescent dye Propidium Iodide 
(PI) and measured by flow cytometry. HD-MyZ, L-540 e HDLM-2 cell lines (1 x 106) were cultured in 
the absence or in the presence of perifosine and sorafenib used as single agents or in combination for 
48 hours. All cells were washed with PBS and fixed in 70% ethanol and kept at 4°C before DNA 
staining with PI. Fixed cells were washed with PBS to remove ethanol, stained with 2.5 µg/ml PI 
(Calbiochem, Darmstadt, Germany) in the presence of 12.5 µg/ml RNAse (Sigma-tau, Rome, Italy), 
and incubated overnight at 4°C before analysis. The number of cells at different cell cycles was 
measured by a (FACS)Calibur flow cytometry system (B-D). The histograms were analyzed with 
FlowJo software (Tree Star). 
 
3.4.4 Measurement of mitochondrial membrane  depolarization (ΔΨm) 
 
Mitochondrial membrane depolarization ('(m) was determined by using the fluorescent probe 
TMRE (Invitrogen, Oregon, USA).204,205 Briefly, cells (1 x 106/mL) were incubated with 50 nM TMRE 
(37°C, 10 minutes) in the dark and analyzed by flow cytometry using a (FACS)Calibur flow 
cytometry system (B-D). The fluorescent dye TMRE is accumulated by mitochondria and as a results 
of mitochondrial membrane depolarization, a shift to the left in the emission spectrum by apoptotic 
cells can be detected. Percentual of TMRE- cells were analyzed with FlowJo software (Tree Star). 
 
3.4.5 Caspase inhibition assay 
 
To gain a better understanding of the mechanism of apoptosis potentiated by perifosine and 
sorafenib, effects of these agents alone or in combination on caspase-dependent and -independent 
apoptosis were investigated. L-540 cell line were coltured in the presence or absence of the pan-
caspase inhibitor, Z-VADfmk (50 µM) (R&D Systems, Abingdon, UK, EU) administered 1 hour prior 
to treatment with perifosine and sorafenib used alone or in combination. After 48 – 72 hours 
exposure to perifosine and sorafenib dead cells and mitochondrial membrane depolarization were 
analyzed by flow cytometry for staining with Annexin-V/PI and TMRE (see paragraphs 3.4.2, 3.4.4). 
 
3.5 SUBCELLULAR FRACTIONS AND WESTERN BLOT ANALYSIS 
 
Total proteins were extracted from 5 × 106 HD-MyZ, L-540 and HDLM-2 cells cultured without or 
with perifosine, sorafenib or perifosine/sorafenib. At different time points, cells were collected, 
washed in ice-cold PBS (Lonza), and homogenized in NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl 
pH 8, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM sodium orthovanadate, 10 µg/mL aprotinin, 
10 µg/mL leupeptin). Mitochondrial/Cytosolic fractions were obtained with a 
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Mitochondria/Cytosol Fractionation Kit (Biovision, CA, USA) according to the manufacturer’s 
instructions. The purity of mitochondrial and cytosolic fractions was determined by Western blot 
analysis using anti-HSP60 antibody (Cell Signaling, Danvers, MA, USA). Protein concentrations 
were determined using the Bradford protein assay (Bio-Rad Laboratories, Milano, Italy, EU). Cell 
lysates (40 µg) were resolved by electrophoresis on 10 – 12% precast polyacrylamide gels (Bio-Rad) 
and transferred to nitrocellulose membranes (Amersham, Pittsburgh, PA). After the membranes 
were blocked in Tris-buffered saline solution (0.1% Tween-20 (TBS-T), 1% bovine serum albumin 
(BSA) and 3% ovalbumin) (Sigma-Aldrich, Milano, Italy, EU), blots were hybridized overnight with 
the appropriate primary antibody. After hybridization with horseradish peroxidase (HRP)-
conjugated secondary antibody, immunocomplexes were visualized using an enhanced 
chemiluminescence Western blotting detection system (Amersham Biosciences, Milan, Italy, EU). 
Blotting analysis was performed using anti- AIF, -Cytochrome c, -Mcl-1, anti-phospho-MEK, -ERK, -
AKT(T308), -S6, anti-p38α and anti-caspase-8 antibodies (Cell Signaling), anti-caspase-3 antibody 
(Santa Cruz, San Diego, CA, USA), anti-caspase-9, anti-poly(ADP-ribose)polymerase (PARP) 
antibodies (B-D) and anti-TRIB3 (Sigma-Aldrich) antibody.  To normalize the amount of loaded 
protein, all blots were stripped and reprobed with rabbit polyclonal antibody anti-β-actin 
(Amersham Biosciences). Full-range Rainbow molecular marker (12-225 kDa, Amersham, GE 
Healthcare) was run in parallel in each sodium dodecyl sulphate - polyAcrylamide gel 
electrophoresis (SDS-PAGE) analyses. Images were acquired on ArtixScan F1 scanner (Microtek 
International Inc., Hsin-Chu, Taiwan) using SilverFast Launcher software (MicrotekSDK) and 
processed with Photoshop CS4 software (Adobe Systems Incorporated, San Jose, CA). Quantitation 
was done using ImageJ software (NIH). The values indicated above each protein band represent 
densitometric ratios of cells treated with perifosine, sorafenib or the combination and the control 
vehicle-treated cells, normalized to β-actin.  
 
3.6 PHOSPHO-KINASE PROTEOME PROFILER ARRAY 
 
To assess the basal phosphorylation levels of serine/threonine/tyrosine kinases in the PI3K/Akt 
signaling pathways of HD-MyZ, L-540 and HDLM-2 cell lines, we used the human phospho-Kinase 
proteome profiler array (R&D Systems, Minneapolis, MN, USA) in accordance with the 
manufacturer’s protocol. Briefly, exponentially growing cell lines (107 cells) were washed with ice-
cold DPBS and solubilized in NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl pH 8, 137 mM NaCl, 
10% glycerol, 2 mM EDTA, 1 mM sodium orthovanadate, 10 µg/mL aprotinin, 10 µg/mL leupeptin) 
by gently rocking the lysates (30 minutes, 4°C). Cell lysates were then centrifuged (14,000 rpm, 5 
minutes, 4°C), and supernatants were transferred into a clean test tube to determine protein 
concentrations using the Bradford protein assay (Bio-Rad Laboratories), followed by storage at -
80°C until use. According to the manufacturer’s instructions, equal amounts of proteins (200 µg) 
from basal control cells were incubated with the human phospho-Kinase array kit. The following 
kinases were detected: Akt (S473), Akt (T308), TOR (S2448), GSK-3α/β (S21/S9), p70S6Kinase 
(T229), p70S6Kinase (T389), p70S6Kinase (T421/S424). Phospho-Kinase array data developed on X-
ray films (Amersham Biosciences) following exposure to chemiluminescent reagents were scanned 
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and analyzed using the open source imaging software ImageJ (NIH). The assays were conducted in 
duplicate, using samples from independent experiments, and produced similar results. A 
background value was determined for each array, using negative controls and empty spots 
positioned in clear areas. This average background signal was subtracted from each spot to 
normalize the values obtained. 
 
3.6.1 Densitometric analysis  
 
Autoradiography protein array films were scanned by ArtixScan F1 scanner (Microtek International 
Inc.) to quantitative Akt (S473), Akt (T308), TOR (S2448), GSK-3α/β (S21/S9), p70S6Kinase (T229), 
p70S6Kinase (T389), and p70S6Kinase (T421/S424) expression, and the images were quantified 
using ImageJ software (NIH). Below there is a brief schematic representation of how to analyze 
proteome profiler array using ImageJ software. After selecting each lane with a rectangular selection 
(Figure 3.1, Step 1), ImageJ generates the lane profile plots (Figure 3.1, Step 2) where each peak of 
interest refers to the expression intensity of the respective dot blot. Then the software labels each 
measured peak with its size as a percent of the total size of the measured peaks (Figure 3.1, Step 3). 
 
 
 
Figure 3.1: Schematic representation of ImageJ densitometric analysis. 
 
3.7 GENOME-WIDE EXPRESSION PROFILING OF HODGKIN LYMPHOMA 
LINES TREATED WITH PERIFOSINE, SORAFENIB AND THEIR 
COMBINATION 
 
Cells from three HL cell lines (HD-MyZ, L-540 and HDLM-2) were treated with perifosine (10 µM), 
sorafenib (5 µM), or their combination for 24 hours. Three biological replicates of untreated and 
drug-treated cells were set up. Total RNA was isolated using TriZol (Invitrogen) reagent, according 
to the manufacturer’s instructions.  After a clean-up treatment with RNAeasy kit following the 
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manufacture’s recommendations (Qiagen, Milano, Italy, EU) and with RNase-free DNase to remove 
contaminating genomic DNA, RNA integrity and purity was assessed by Bioanalyzer (Agilent). 
Single-color hybridization of RNAs was performed on Illumina Bead Chip HumanHT-12_v3 
Microarrays (Illumina San Diego, CA) containing more than 48,000 transcript probes. The 
expression profiles have been deposited in NCBI’s Gene Expression Omnibus (GEO) with GSE 
accession number GSE31060. Background correction, filtering of data, and quantile normalization 
were done using the BeadStudio Illumina software. The BRB-array Tools (Vers.4.2.0) software was 
used to identify genes significantly modulated by any of the drug treatments.  To this end, we 
carried out Class Comparison with a random-variance F-test analysis carried out at  P =.005. 
Permutation P values for significant genes were computed based on 10,000 random permutations. 
Pairwise comparison for differential modulation of each gene by any two treatments was carried out 
at P =.01. Clustering of significantly modulated genes was done by Cluster 3.0 software using 
centered correlation as distance metric and complete linkage clustering. Heat maps were visualized 
by Java Treeview software. Ingenuity Pathway Analysis (IPA 8.5, www.ingenuity.com) was used to 
analyze the network connections, functions and canonical pathways of the identified genes. 
 
3.8 REAL-TIME REVERSE TRANSCRIPTASE-PCR (RT-PCR) 
  
Total RNA (1 µg) used for microarray experiments (for cell lines, independent RNA preparations 
were used) was reverse-transcribed using the High-Capacity cDNA Archive Kit (Applied 
Biosystems, Foster City, CA, USA). The expression of TRIB3, DDIT4, CCNE1, CDC25A, and 
PLEKHF1 genes was determined using a TaqMan based real-time PCR method. To analyze and 
quantify the levels of the TRIB3, DDIT4, CCNE1, CDC25A, and PLEKHF1 genes, we used a TaqMan 
isoform-specific probe (assay no. Hs01082394_m1; Hs01111686_g1; Hs01026536_m1; 
Hs00947994_m1; Hs00759096_s1, respectively) (Applied Biosystems). Amplification was performed 
using a total reaction volume of 25 µl in a MicroAmp Optical 96-well reaction plate. All real-time 
PCR reactions were carried out with TaqMan Universal Master Mix. Reactions were run on the ABI 
Prism 7000 sequence detection system (Applied Biosystems) using the following conditions: 50 °C 
for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. 
Quantification analysis was performed by the ''Ct method and statistically analyzed by GraphPad 
Prism software (GraphPad Software Inc., San Diego, CA, USA). Data were normalized to the 
expression levels of the housekeeping #2-microglobulina gene. 
 
3.9 siRNA GENE SILENCING 
 
L-540 cells were transfected with 100 nM Hs_TRIB3_5 FlexiTube siRNA premix-reagent or negative 
control siRNA premix-reagent (Qiagen, Milano, Italy, EU) following the instructions of the 
manufacturer. Cells (0.4 × 106/mL) were plated and transfected with the given siRNAs. After 24 
hours, the cells were treated with perifosine and sorafenib as indicated. Gene silencing effects were 
evaluated by Western blot and Viable cell counting as described above after the indicated times of 
treatment. 
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3.10 IN VIVO EXPERIMENTAL MODEL 
 
3.10.1 In vivo activity of perifosine/sorafenib in tumor-bearing non-obese 
diabetic/severe combined immunodeficient (NOD/SCID) mice  
 
Six- to eight-week-old NOD/SCID mice with a body weight of 20 to 25 g were purchased from 
Charles River (Milano, Italy, EU) and xenografted with HD-MyZ, L-540, or HDLM-2 cell lines. Mice 
were housed under standard laboratory conditions according to our institutional guidelines. Animal 
experiments were performed according to the Italian laws (D.L. 116/92 and following additions), 
which enforce the EU 86/109 Directive, and were approved by the institutional Ethical Committee 
for Animal Experimentation. Mice were inoculated intravenously (IV) with HD-MyZ (1.8 x 106 
cells/mouse). After 3 days HD-MyZ injection, mice were randomized in four groups (n=5/group, 
for a total of two different experiments) to receive per os (PO) injections of perifosine (7.5 
mg/kg/mouse/5die/5weeks) and/or intraperitoneal (IP) injections of sorafenib (60 
mg/kg/mouse/5die/5weeks), or control NaCl solution 0.9%. Endpoint of in vivo IV experiments 
was death.  
 
HD-MyZ (5 × 106 cells/mouse), L-540 and HDLM-2 (25 × 106 cells/mouse) cells were inoculated 
subcutaneously (SC) in the right flank of each mouse. When tumor volume reached approximately 
100 mg in weight (10 days after tumor inoculation), mice were randomly assigned to receive either a 
short- or long-term treatment with perifosine and/or sorafenib or control vehicle. The short-term 
treatment consisting of perifosine (30 mg/kg/mouse, PO) or sorafenib (90 mg/kg/mouse, IP) (alone 
or in combination) or control vehicle, for 5 days was used to assess necrotic and apoptotic areas.  
For the long-term treatment 25 × 106 cells/mouse of L-540 and HDLM-2 cell lines were SC 
inoculated in the right flank of each mouse. After 7 and 11 days from tumor cells inoculum, mice 
were treated with perifosine (15 mg/Kg/mouse, PO) and/or sorafenib (30 mg/Kg/mouse, IP) or 
control vehicle 5 days per week for 3 weeks (days 7 – 25 from tumor inoculum for L-540 model; days 
11 – 29 from tumor inoculum for HDLM-2 model). The endpoint of the long-term treatment was 
tumor weight. Mice were checked twice weekly for tumor appearance, body weight measurements 
and toxicity. The tumors were measured with calipers, and their weights were calculated using the 
formula: (a × b2)/2, where a and b represented the longest and shortest diameters, respectively. 
Antitumor efficacy was measured as tumor growth inhibition (TGI) defined as [1 - (T/C) × 100], 
where T and C are the mean tumor weight in the treated and untreated control groups, respectively. 
Each experiment was performed on at least two separate occasions, using five mice per treatment 
group. 
 
3.10.2 Tumor sample processing 
 
Paraffin-embedded tumor nodules were processed for immunohistochemistry and 
immunofluorescence analyis. 
Tumor nodules were fixed in formalin (10% neutral buffered formalin) and embedded in paraffin 
under the following procedure. 
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Table 3.1: Tumor sample processing scheme. 
 
REAGENT ALTERNATING 
PRESSURE AND 
VACUUM 
TIME       (hours) TEMPERATURE     (°C) 
Formalin - 8 Room Temperature (RT) 
Ethanol 70% + 1 RT 
Ethanol 95% + 1,30 RT 
Ethanol 95% + 2 RT 
Ethanol 100% + 1 RT 
Ethanol 100% + 1,30 RT 
Ethanol 100% + 2 RT 
Xylene + 2 RT 
Xylene + 2 RT 
Paraffin + 1,30 60 
Paraffin + 1,30 60 
Paraffin + 2 60 
 
Paraffin-embedded tumor nodules were cut in a microtome to the desired thickness (2 µm) and 
affixed onto the slide. Nodule sections were mounted on positively charged coated slides and dried 
(60°C for 1 hour) to remove any water that may be trapped under the section. 
 
3.10.3 Histological analysis of tumor nodules 
 
Sections from formalin-fixed, paraffin-embedded tumor nodules (thickness of 2 µm) were dewaxed, 
hydrated and stained with hematoxylin and eosin. Apoptosis and tumor necrosis were detected 
using TdT-mediated dUTP nick end-labeling (TUNEL) staining (Roche, Milano, Italy, EU) according 
to the manufacturer’s instructions. Positive signal was revealed by 3,3’-diaminibenzidine staining 
and tumor sections were then counterstained with hematoxylin, rapidly dehydrated using graded 
ethanols to xylene, and mounted in a drop of fast-drying mounting medium. 
 
3.10.4 Immunohistochemistry 
 
Sections (2 µm thick) from formalin-fixed paraffin-embedded HL lymphonode blocks were dewaxed 
and hydrated. Epitope retrieval was performed with 2 mM EDTA pH 8 for 30 min at 95°C. Sections 
were then rinsed with PBS containing 0.05% Tween 20 and blocked with Ultra V Block (Thermo 
Scientific) for 10 minutes at RT. Rabbit anti-human phospho-S6 (1:80) (Cell Signaling), and rabbit 
anti-human phospho-ERK1/2 (1:60) (Cell Signaling) antibodies were incubated for 1 hour at RT. 
UltraVision LP detection system (Thermo Scientific) was used to reveal antigen positivity. Finally, 
after rinsing with PBS containing 0.05% Tween 20, sections were counterstained with hematoxylin, 
rapidly dehydrated using graded ethanols to xylene, and mounted in a drop of fast-drying 
mounting medium. 
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3.10.5 Immunofluorescence and confocal microscopy 
 
Sections from formalin-fixed, paraffin-embedded tumor nodules (thickness of 2 µm) were dewaxed 
and hydrated. Epitope retrieval was performed with 10 mM Sodium Citrate buffer pH 6 for 10 min 
at 95°C. Sections were then rinsed with PBS containing 0.05% Tween 20 and blocked with Ultra V 
Block (Thermo Scientific) for 10 minutes at RT. Rabbit anti-human DDIT4 (1:50) (Sigma, St. Louis, 
MO, USA) and rabbit anti-human TRIB3 (1:100) (Sigma, St. Louis, MO, USA) antibodies were 
incubated for 1 hour at RT. After being washed in PBS containing 0.05% Tween 20, sections were 
incubated with the appropriate Alexa Fluor 568-conjugated secondary antibody (Invitrogen) for 30 
minutes at RT. Finally, after rinsing with PBS containing 0.05% Tween 20, sections were incubated 
with TO-PRO-3 nuclear dye (1:10000) (Invitrogen) for 20 minutes at RT. After mounting in a drop of 
anti-bleaching mounting medium (Vectashield, Vector Laboratories, Burlingame, CA, USA), sections 
were examined under an epifluorescent microscope equipped with a laser confocal system (MRC-
1024, Bio-Rad Laboratories, Milano, Italy, EU). Image processing was carried out using LaserSharp 
computer software (Bio-Rad Laboratories). 
 
3.10.6 Analysis of stained sections 
 
After TUNEL staining, entire tissue sections were acquired at 20× magnification with an automatic 
high-resolution scanner (dotSlide System, Olympus, Tokyo, Japan) and subdivided into a collection 
of non-overlapping red, green, and blue (RGB) images in TIFF format (final resolution 3.125 
pixels/µm). For necrosis quantification images were acquired at 2x magnification without further 
subdivision. Image analysis was carried out using the open-source ImageJ software 
(http://rsb.info.nih.gov/ij/). Routines for image analysis were coded in ImageJ macro language 
and executed on RGB images without further treatment. Per each experimental condition, at least 
three sections from different tumor nodules were analyzed. The number of total and TUNEL+ cells 
per section was counted as follows. Briefly, the dynamic range of images was expanded to full by 
contrast enhancement, and cells were identified by appropriate filtering in the RGB channels. 
Resulting black and white images were combined to represent only pixels selected in every color 
channel. For each image, both total and TUNEL+ cells were counted by the ImageJ internal function 
for particle analysis. TUNEL-stained sections were also analyzed for the presence of necrotic areas. 
Images were at first treated for noise reduction by application of a median filter with a 1.5-pixel 
radius. Then, necrotic and total tissue areas were recognized using different filter values under 
direct human supervision. Black areas in the final binary images were quantified in terms of pixel 
counts to obtain a percent necrotic index expressed as (necrotic area)/(total tissue area) × 100. Per 
each parameter, the accuracy and appropriate cut-off levels were determined by comparing filtered, 
black and white images to the RGB originals. Automatic routines were validated by comparing 
results with those obtained by visual counting of up to 10% of the total images.  
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3.11 STATISTICAL ANALYSIS 
 
Statistical analysis was performed with the statistical package Prism 5 (GraphPad Software, San 
Diego, CA, USA) run on a Macintosh Pro personal computer (Apple Computer Inc.). To test the 
probability of in vitro significant differences between untreated and treated samples, the two-way 
analysis of variance (ANOVA) was used, and individual group comparisons were evaluated by 
Bonferroni post-test.  Survival curves were created using the product limit method of Kaplan-Meier 
and survival differences were compared using the logrank test. Tumour volume data from the in-
vivo study were analysed with two-way analysis of variance (ANOVA), and individual group 
comparisons were evaluated by Bonferroni post-test. TUNEL staining data was statistically 
analyzed with one-way analysis of variance (ANOVA), and individual group comparisons 
were evaluated by Bonferroni post-test. Differences were considered significant if P ≤.05. 
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4. RESULTS 
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4.1 ACTIVATION OF THE MAPK AND PI3K/Akt SIGNALING PATHWAYS IN 
HODGKIN LYMPHOMA SAMPLES FROM HL PATIENTS 
 
To examine activation of the MAPK and PI3K/Akt pathways in paraffin-embedded human 
Hodgkin lymphoma tissues, immunohistochemistry was performed on primary tumor samples 
from 2 HL patients using antibodies against phospho-ERK1/2 and phospho-S6.  
For immunohistochemistry, staining of a nonmalignant reactive lymph node specimen was used as 
a positive control for phospho-ERK1/2 and phospho-S6 expression. Phosphorylation of phospho-
ERK1/2 and phospho-S6 was detected in both HL lymphomas (Figure 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Activation of MAPK and PI3K/Akt signaling in HL. Constitutive activation of the MAPK and 
PI3K/Akt signaling pathways in patient samples of HL. Activation of ERK1/2 and S6 was assessed in HL 
tissue by immunohistochemistry with phosphospecific antibodies for ERK1/2 and S6. Shown is a section from 
a nonmalignant reactive lymph node and an example of two cases of classical HD. 
 
4.2 BIOLOGICAL EFFECT OF PERIFOSINE AND SORAFENIB AS SINGLE 
AGENTS ON HL CELL LINES 
 
To further characterize the in vitro effects of perifosine and sorafenib, we performed cell 
proliferation assays. To that end, we tested increasing concentrations of the drug in each cell line 
measuring cell proliferation by cell counting and viability experiments. 
 
4.2.1 Growth inhibition by perifosine and sorafenib  
 
The finding that the MAPK and PI3K/Akt signaling pathways are constitutively activated in 
primary HL tissue suggested that MAPK and PI3K/Akt dual-inhibition might inhibit growth of 
these cells. Three representative HL cell lines, HD-MyZ, L-540, and HDLM-2, were treated with 
increasing doses of perifosine and sorafenib (1 µM – 10 µM) for 48 and 72 hours and assessed for the 
effects on proliferation and survival (Figure 4.2A-B). We evaluated perifosine and sorafenib 
antitumor activity in term of annexin-V-/PI- cells after 48 – 72 hours. Whereas perifosine induced a 
dose- and time-dependent decrease of cell proliferation in two out of three cell lines, sorafenib 
reduced viable cell countings in all cell lines. The HD-MyZ cell line was the most sensitive to 
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perifosine, showing a 50% growth inhibition (IC50) value of 6.1 µM after 72 hours (Figure 4.2A). The 
HDLM-2 cell line was the most resistant to perifosine, in which perifosine at 10 µM decreased cell 
survival by <20% at 72 hours without evidence of a dose-dependent effect (Figure 4.2A). All the 
tested cell lines exhibited moderate response to sorafenib with IC50s ranging from 3 to 8 µM (Figure 
4.2B) at 72 hours, which are within the clinically achievable and steady-state plasma levels of 15 to 
20 µM.200,206 
 
Figure 4.2: Effect of perifosine and sorafenib on growth of HD-MyZ, L-540 and HDLM-2 cells. HD-MyZ, L-540 
and HDLM-2 cells were plated as described in “Materials and Methods” for the period indicated on the graph. 
Perifosine (A) or sorafenib (B) were added at increasing concentrations and compared with controls. After 
specified period of drug exposure (either 48 or 72 hours), absolute cell counts were obtained using Flow-Count 
beads and Annexin-V/Propidium Iodide (PI) staining. Viable cells are expressed as Annexin-V-/PI- cells. The 
fractions of viable cell counts in drug-treated cells are plotted against drug concentration. Each statistical  error 
bar (± SEM) represents four independent experiments. 
 
4.3 IN VITRO BIOLOGICAL EFFECT OF PERIFOSINE AND SORAFENIB AS 
COMBINED AGENTS IN HL CELL LINES  
 
4.3.1 Perifosine and sorafenib combined treatment inhibit the growth of HL cells  
 
To evaluate potential synergy, we used perifosine and sorafenib at concentrations below IC50 values. 
Both drugs were added simultaneously in the HD-MyZ and HDLM-2 cells, whereas with one drug 
preceding the other by 24 hours in L-540 cell line. As presented in Figure 4.3, the combination of 
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perifosine and sorafenib was more potent than each single agent alone in decreasing the survival of 
HD-MyZ and L-540 cells. Perifosine 2.5 µM and sorafenib 2.5 µM alone decreased the survival of 
HD-MyZ cells by less than 20%, whereas their combination decreased cell survival by greater than 
40% at 72 hours (Figure 4.3). Viable cell counts was reduced by 50% following individual (5 µM) 
perifosine or (5 µM) sorafenib treatment and co-treatment further enhanced the reduction up to 74% 
in L-540 cell line at 72 hours (Figure 4.3). This enhanced effect was absent in HDLM-2 cells. This 
result further demonstrates that the combination of perifosine and sorafenib exhibits a more than 
additive (i.e., synergistic) effect on inhibition of cell growth.  
 
 
Figure 4.3: Coadministration of perifosine and sorafenib results in a marked cell growth reduction of Hodgkin 
lymphoma cells. HD-MyZ, L-540 and HDLM-2 cells were exposed to perifosine ( green) and sorafenib (  
blue) alone or in combination (u red) for 48 and 72 hours after which viable cell counts were obtained as 
described in Materials and Methods. Both drugs were added simultaneously in the HD-MyZ and HDLM-2 
cells, whereas with perifosine preceding sorafenib by 24 hours in L-540 cell line. Mean (± SEM) values refer to 
three independent experiments. * P <.0001, ° P <.001, and ≠ P <.01, compared to single treatments (perifosine, 
green; sorafenib, blue). 
 
4.3.2 Perifosine in combination with sorafenib enhances apoptosis in HL cells 
 
We further examined if the cytotoxic effects of perifosine/sorafenib combined treatment were 
mediated through the induction of apoptotic cell death in HD-MyZ, L-540 and HDLM-2 cell lines. 
As shown in Figure 4.4, perifosine in combination with sorafenib induced a significant (P ≤.05 at 
least) increase in apoptotic cells only in L-540 cell line, compared to single treatments, as indicated 
by AnnexinV/PI staining. After 72 hours-exposure to concentrations of 5 µM perifosine and 5 µM 
sorafenib, the combination treatment induced cell death in 74% of L-540 cells, whereas apoptosis 
was induced only in 30% of the HDLM-2 cells, suggesting that the L-540 cells were more sensitive to 
perifosine/sorafenib-induced apoptosis (Figure 4.4). The HD-MyZ cells were resistent to perifosine 
and sorafenib-induced apoptosis both as single drugs and in combination.  
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Figure 4.4: Coadministration of perifosine and sorafenib results in a striking increase in apoptosis of Hodgkin 
lymphoma cells. HD-MyZ, L-540 and HDLM-2 cells were exposed to perifosine ( green) and sorafenib (  
blue) alone or in combination (u red) for 48 and 72 hours after which the percentage of apoptotic cells was 
assessed by annexin-V/PI double staining and flow cytometry analysis as described in Materials and Methods. 
Both drugs were added simultaneously in the HD-MyZ and HDLM-2 cells, whereas with perifosine preceding 
sorafenib by 24 hours in L-540 cell line. Mean (± SEM) values refer to three independent experiments. * P 
<.0001, ° P <.001, and ≠ P <.01, compared to single treatments (perifosine, green; sorafenib, blue). 
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4.3.3 Effect of combined perifosine and sorafenib on cell cycle progression  
 
Because perifosine in combination with sorafenib is effective in decreasing cell number in HD-MyZ 
and L-540 cells (Figure 4.3), we further examined cell cycle alteration in HD-MyZ, L-540 and HDLM-
2 cell lines after exposure to perifosine and sorafenib used as single agents or in combination (Table 
4.1).  
 
Table 4.1: Modulation of the cell cycle profile by perifosine and sorafenib. Distribution of HL cells, cultured in 
the absence (Ctrl) or presence of perifosine and/or sorafenib, in the different phases of the cell cycle calculated 
from the flow cytograms after PI staining, and expressed as the percentage of the total population. Data are 
expressed as means ± SEM of results from three independent experiments. * P <.0001 and ≠ P <.05 compared to 
control, ° P <.01 and § P <.05 compared to single treatments. 
 
CELLS TREATMENT sub-G0 (%) G0/G1 (%) S (%) G2/M (%) 
HD-MyZ 
Ctlr 0.4 ± 0.01 34 ± 0.3 33 ± 1 32 ± 1 
Perifosine (2.5 µM) 0.5 ± 0.01 36 ± 0.6 29 ± 1 35 ± 1 
Sorafenib (2.5 µM) 0.6 ± 0.01 32 ± 0.4 33 ± 1 34 ± 1 
Perif/Soraf 1.7 ± 0.03 34 ± 2.6 11 ±  2.5*≠ 53 ±  3*≠ 
L-540 
Ctlr 4 ± 0.3 39 ± 4 37 ± 1 20 ± 6 
Perifosine (5 µM) 6 ± 0.8 33 ± 1 30 ± 2 30 ± 3 
Sorafenib (5 µM) 12 ± 0.3 35 ± 4 29 ± 0.5 24 ± 3 
Perif/Soraf 18 ±  3≠ 51 ± 1 15 ±  0.5*§ 15 ± 3 
HDLM-2 
Ctlr 3 ± 0.3 42 ± 0.7 35 ± 0.7 20 ± 0.1 
Perifosine (5 µM) 3 ± 0.6 35 ± 2.4 36 ± 0.2 25 ± 1.6 
Sorafenib (5 µM) 9 ± 0.9 50 ± 2.5 30 ± 0.5 10 ± 1.7 
Perif/Soraf 9 ± 1 46 ± 3.4 29 ± 1.5 14 ± 0.4 
 
Cell cycle analysis revealed that perifosine/sorafenib treatment resulted in the accumulation of HD-
MyZ-treated cells in the G2/M phase without induction of apoptosis (Figure 4.5). Proliferating 
control HD-MyZ cells yielded 34% cells in the G0/G1 phase, 33% cells in the S phase, and 32% cells 
in G2/M phase of cell cycle 48 hours after treatment. Concordant with the growth inhibition data 
(Figure 4.3), HD-MyZ cells were minimally perturbed by either 2.5 µM perifosine or 2.5 µM 
sorafenib, whereas the combination causes a consistent increase in G2/M (to 53%) along with virtual 
loss of the S-phase (11%) fraction, furthermore minimally increased the sub-G0 fraction, indicating 
that the perifosine/sorafenib-antiproliferative effect was predominantly due to a cytostatic, rather 
than a cytotoxic effect in the HD-MyZ cells (Figure 4.5). Similarly, cell cycle analysis of the L-540 
cells (Figure 4.5) indicated that individual treatment of either perifosine or sorafenib (at 5 µM, 
respectively) had a marginal effect, whereas combined treatment of perifosine and sorafenib led also 
to virtual loss of the S-phase population and retention of G0/G1 populations after 48 hours. 
Therefore, we detected 38%, 33%, 35%, and 51% G0/G1 cells in L-540 cells treated with control 
vehicle, 5 µM perifosine, 5 µM sorafenib, and the combination treatment respectively, after 48 hours. 
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Interestingly, perifosine in combination with sorafenib significantly reduced the percentage of the 
cells in the S- and G0/G1-phases (15% and 51%, respectively) and strongly increased the sub-G0 
fraction (18%) indicating that perifosine/sorafenib primarily decreases cell numbers in L-540 cells 
via cell cycle arrest with induction of apoptosis (Figure 4.5). No significant cell cycle alterations were 
assessed in HDLM-2 cell line, further supporting its resistance to perifosine/sorafenib-treatment 
(Figure 4.5). In the following studies, we focused on revealing the mechanisms underlying 
perifosine/sorafenib-induced apoptosis. 
 
 
Figure 4.5: Perifosine/sorafenib treatment induced cell cycle arrest in HL cells. Cell cycle analysis of combined 
treatment of perifosine (2.5µM) and sorafenib (2.5µM) on HD-MyZ, and perifosine (5µM) and sorafenib (5µM) 
on L-540 and HDLM-2 cells after 48 hours. Flow cytometry was done to define the cell cycle distribution in 
comparison to untreated controls. Both drugs were added simultaneously in the HD-MyZ and HDLM-2 cells, 
whereas with perifosine preceding sorafenib by 24 hours in L-540 cell line. Mean (± SEM) values refer to three 
independent experiments. * P <.0001 and ≠ P <.05 compared to control, ° P <.01 and § P <.05 compared to single 
treatments. 
 
4.4 MECHANISM OF PERIFOSINE/SORAFENIB-INDUCED CELL DEATH 
 
4.4.1 Perifosine- and sorafenib-potentiated apoptosis was caspase-independent 
 
Previous studies investigating the mechanism(s) of perifosine and sorafenib-induced apoptosis 
showed different pathways of cell death, involving both caspase-dependent146,207 or caspase-
independent208,209 mechanisms. To gain a better understanding of the mechanism of apoptosis 
potentiated by perifosine and sorafenib in HL cells, effects of these agents alone or in combination 
on caspase-dependent and -independent apoptosis were investigated. Perifosine and sorafenib 
treatment had no marked effect on the activity of caspase 3, 8, 9 and PARP in HD-MyZ, L-540 and 
HDLM-2 cell lines at 48 hours (Figure 4.6).  
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Figure 4.6: Perifosine in combination with sorafenib does not induce processing of the caspases or PARP. HD-
MyZ, L-540 and HDLM-2 cells were treated with perifosine (5µM), sorafenib (5 µM) alone or in combination for 
48 hours. Whole-cell lysates were obtained and Western blot analysis employed to monitor caspase 
cleavage/activation and PARP degradation. Equal protein loading was confirmed by blotting for β-actin. No 
processing of the caspases or PARP was observed. CF, indicates cleaved fragments. 
 
The role of caspases in apoptosis potentiated by perifosine and sorafenib was further tested by 
pretreating L-540 cells with Z-VADfmk, a pan-caspase inhibitor. Consistent with its inhibition of 
caspase activity, Z-VADfmk significantly reduced the apoptosis induced by sTRAIL (10 ng/ml) 
from 47% to 16% (P <.0001) in KMS-11 cell line (data not shown); however, it had no apparent effect 
on apoptosis potentiated by the perifosine and sorafenib combination in L-540 cell line, further 
supporting that perifosine/sorafenib acts through a caspase-independent pathway (Figure 4.7).  
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Figure 4.7: Combined exposure of HL cells to perifosine and sorafenib led to caspase-independent cell death. L-
540 cells were pre-treated with 50 µM Z-VADfmk for 1 hours then treated with 5 µM perifosine ± 5 µM 
sorafenib for 48 hours. Following treatments, cell death was assayed by flow cytometry using the Annexin V/PI 
double staining. * P <.0001 compared to sorafenib alone, ° P <.001 compared to perifosine alone. Columns, 
mean; bars, SEM. 
 
4.4.2 Cotreatment with perifosine and sorafenib results in a marked Bax 
conformational change and translocation to the mitochondrial fraction, and 
release of the mitochondrial cytochrome c and AIF 
 
In general, apoptotic signals converge toward the multi-domain pro-apoptotic proteins Bax and Bak. 
While Bak is localized in the organelle membranes, particularly in the mitochondria where it 
undergoes conformational change upon apoptotic stimuli, Bax is primarily distributed in the cytosol 
in non-apoptotic cells. Upon diverse apoptotic stimuli, Bax undergoes conformational change, 
accompanied by translocation into the mitochondrial membrane, promoting the release of pro-
apoptotic mitochondrial proteins (e.g., cytochrome c) into the cytosol and inducing apoptosis.210 
Therefore, the effects of combined ERK1/2 and PI3-K/Akt inhibition were examined in relation to 
Bak and Bax conformational change and intracellular Bax localization. Individual treatment (48 – 72 
hours) with perifosine or sorafenib modestly induced Bax translocation, whereas combined 
treatment dramatically increased mitochondrial translocation (Figure 4.8). Consistent with these 
findings, combined treatment with perifosine and sorafenib (48 – 72 hours) resulted in a pronounced 
increase in AIF and cytochrome c cytosolic release whereas no effect were observed when perifosine 
or sorafenib were administered individually (Figure 4.8). These findings indicate that perifosine and 
sorafenib cooperate to promote Bax and Bak conformational change, Bax mitochondrial 
translocation, and AIF and cytochrome c cytosolic release. 
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Figure 4.8: Perifosine/sorafenib combined treatment induces conformationale change of Bax, cytosolic release 
of cytochrome-c and AIF. L-540 cells were exposed to 5 µM sorafenib and 5 µM perifosine alone or in 
combination for 48–72 hours, after which mitochondrial and cytosolic fractions were obtained and subjected to 
Western blot analysis, as explained in Material and Methods section, to monitor conformationale change of Bax, 
release of cytochrome-c and apoptosis-inducing factor (AIF). The purity of mitochondrial and cytosolic 
fractions was determined by Western blot analysis using anti-HSP60 antibody. Equal protein loading was 
confirmed by blotting for β-actin. 
 
4.4.3 Cotreatment with perifosine and sorafenib results in marked mitochondrial 
damage 
 
To further examine the molecular mechanism(s) whereby perifosine/sorafenib triggers cell death, 
we investigated whether loss of mitochondrial potential was involved in perifosine/sorafenib-
induced cell death in L-540 cell line. Treatment with perifosine/sorafenib induced a potent time-
dependent mitochondrial membrane depolarization that could be detected in L-540 cell line (Figure 
4.9), with loss of mitochondrial potential being detectable in 40% to 80% of perifosine/sorafenib-
treated cells after 48- and 72-hours, respectively. In addition, perifosine/sorafenib can induce a 
severe mitochondrial injury both in Z-VADfmk pretreated and non-Z-VADfmk treated L-540 cells at 
similar levels further indicating that perifosine/sorafenib treatment can induce apoptosis by 
caspase-independent mechanisms (Figure 4.9). 
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Figure 4.9: Combined exposure of HL cells to perifosine and sorafenib resulted in a marked increase in 
mitochondrial injury. L-540 cells were treated with perifosine (5 µM), sorafenib (5µM), or the combined 
treatment plus Z-VADfmk (50 µM). Treatment with the caspase inhibitor Z-VADfmk was started 1 hour before 
adding perifosine and sorafenib. At the indicated time points, loss of mitochondrial potential (ΔΨm) was 
measured using TMRE staining and flow cytometry. Shown representative dot plots of mitochondrial 
membrane depolarization.  
 
4.5 PATHWAY INHIBITION IN RESPONSE TO PERIFOSINE AND 
SORAFENIB AS COMBINED AGENTS 
 
Since perifosine has been shown to modulate Akt as well as other signaling pathways, including the 
JNK and MAPK pathways, and sorafenib affects the phosphorylation levels of key mediators of the 
RAF/MEK/ERK cascade, we examined whether perifosine in combination with sorafenib enhanced 
the modulation of similar signal transduction pathways in human HL cells. 
 
4.5.1 Baseline phosphorylation of Akt and its downstream target in HL cells 
 
We first examined baseline phosphorylation of Akt and the direct and indirect Akt targets GSK-
3α/β and p70S6 kinase (p70S6K), in HD-MyZ, L-540 and HDLM-2 cell lines, using a sensitive and 
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semiquantitative human phospho-Kinase array kit (R&D Systems, Inc.) (Figure 4.10). In addition, by 
western blotting and densitometric scanning, we observed that HDLM-2 cells have very low basal 
levels of p-Akt, whereas both HD-MyZ and L-540 cells have much higher basal levels of p-Akt. 
When comparing the apoptosis results presented in Figure 4.4, it seems that low basal levels of p-
Akt correlated with low sensitivity to perifosine-induced apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: HD-MyZ, L-540 and HDLM-2 baseline phosphorylation levels of Akt and its downstream targets. 
Shown are data from one of two independent experiments in duplicate. The chemiluminescence signal intensity 
of individual spots was analyzed using the open source imaging software ImageJ (http://rsb.info.nih.gov/ij/).  
 
4.5.2 Perifosine in combination with sorafenib significantly affects 
phosphorylation of MAPK and PI3-K/Akt pathways 
 
HD-MyZ and L-540 responsive cell lines exhibited a significative decrease in p-Akt levels when 
exposed to perifosine/sorafenib (p-Akt levels were only detectable in HD-MyZ cells after 6-hours 
exposure), whereas in HDLM-2 cells, p-Akt levels were unaffected (Figure 4.11). We also detected, 
in HD-MyZ and L-540 cells, a 77-94% decrease, respectively, in the level of p-S6, a well-known 
substrate of Akt, furthering the notion that perifosine in combination with sorafenib inhibits Akt 
signaling in HL cells (Figure 4.11). 
 
In examining MAPK signal transduction pathway, we observed inhibition of MEK1/2 and ERK1/2 
phosphorilations up to 80% and 43%, respectively, 16 hours after perifosine/sorafenib-treatment in 
HD-MyZ cells. In accordance with results relative to phosphorylation reduction, amounts of p-
MEK1/2 and p-ERK1/2 proteins were reduced to a larger extent (61% and 86%, respectively) in L-
540 cells than in HD-MyZ cells. p-38α levels were reduced by 32% in HD-MyZ and by 75% in L-540 
cells, whereas Mcl-1 amounts were reduced by 100% both in HD-MyZ and L-540 cell lines (Figure 
4.11). Interestingly, perifosine/sorafenib combined treatment did not alter the levels of p-MEK1/2, 
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p-ERK1/2 and Mcl-1 but did decrease the levels of p-38α in HDLM-2 cell line (Figure 4.11). These 
results demonstrate that perifosine/sorafenib potently inhibit baseline phosphorylation of Akt and 
its downstream target proteins consistent with downmodulation of MEK, ERK and Mcl-1 
phosphorylation. Furthermore, perifosine in combination with sorafenib downregulates the PI3-
K/Akt and MAPK signaling pathways in a cell line-dependent fashion. 
 
 
 
Figure 4.11: Perifosine/sorafenib treatment induced changes in survival signals in HL cells. Immunoblots of 
extracts from HD-MyZ, L-540 and HDLM-2 cells treated with perifosine (5 µM) and/or sorafenib (5 µM) for 16 
hours. Equal protein loading was confirmed by blotting for β-actin. Quantitation was done using ImageJ 
software (NIH). The values indicated above each protein band represent densitometric ratios of cells treated 
with perifosine, sorafenib or the combination over the control vehicle-treated cells, normalized to β-actin. 
Representative blots are shown. Experiments were repeated twice with similar results. 
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4.6 MODULATION OF GENE EXPRESSION IN HODGKIN LYMPHOMA CELL 
LINES BY PERIFOSINE, SORAFENIB AND THEIR COMBINATION 
 
To gain insight into the effects of perifosine and/or sorafenib on HL cell lines, we carried out 
genome-wide microarray analysis of HD-MyZ, L-540, and HDLM-2 cell lines treated for 24 hours 
with these inhibitors. Heat maps (Figure 4.12) and Venn diagram analysis (Figure 4.13) of 
significantly modulated genes indicated a dominant role of sorafenib in changing gene expression 
levels, with less impact by perifosine, in all three cell lines.  
 
 
 
Figure 4.12: Modulation of gene expression in HL cell lines by perifosine, sorafenib or their combination. One 
way hierarchical clustering of genes (HD-MyZ: n=1242; L-540: n=778; HDLM-2: n=829) showing significant 
modulation (at P =.005 of the univariate F test) by  perifosine and/or sorafenib treatment. Gene-wise median 
centered normalized intensities (in Log space) of untreated cells (CTRL1-3) and of cells treated with perifosine 
(PER1-3), sorafenib (SOR1-3) or the perifosine/sorafenib combination (P+S1-3) are shown. The heat map was 
clustered using centered correlation as distance metric and complete linkage clustering. 
 
In fact, as shown by the Venn diagrams (Figure 4.13) sorafenib modulated a larger number of genes, 
compared to perifosine and most of the genes modulated by “sorafenib only” treatment, remained 
modulated even in the perifosine/sorafenib combination. 
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Figure 4.13: Venn diagram analysis of significantly modulated genes by perifosine, sorafenib or their 
combination in the three HL lines. Numbers indicated in bold underlined  highlight genes significantly 
modulated only by the perifosine/sorafenib combination.  
 
However, in all three cell lines, Venn diagram analysis identified also the genes significantly 
modulated by the perifosine/sorafenib combination (Figure 4.13 lower right circles in each Venn 
diagram and Supplementary Table 1A-C for the identity and fold change values of all significantly 
modulated genes). Volcano plots of the latter subsets of genes indicated that only a small group of 
these genes underwent a strong modulation (i.e. a fold change >1.5) by the perifosine/sorafenib 
treatment (Figure 4.14).  
 
 
 
Figure 4.14: Volcano plots of all genes significantly modulated by the perifosine/sorafenib combination, 
showing extent of modulation (as Log2 Fold Change) vs P value of the univariate F test. Vertical dotted bars: ± 
1.5 fold changes. Horizontal dotted line identifies the P =.005 nominal significance value of the univariate F test. 
 
We then carried out Ingenuity Pathway analysis of the genes significantly modulated by 
perifosine/sorafenib combination (Supplementary Table 2A-C) to classify them according to the 
most relevant networks of interaction, functional classes and canonical pathways. In the most 
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informative cell line (i.e. HD-MyZ, the line showing the largest number of genes modulated by the 
perifosine/sorafenib combination) we found that several of the most up- and down-modulated 
genes (indicated in bold red or green in Supplementary Table 2A, respectively), were part of 
interacting networks and/or had functions related to cellular movement, cell cycle and cell death, 
DNA replication, cellular growth and proliferation. In this cell line, genes inhibited by the 
perifosine/sorafenib combination were part of canonical pathways regulating cell cycle progression 
(Supplementary Table 2A). In the same cell line, we then looked for genes showing enhanced 
modulation by perifosine/sorafenib combined treatment compared to single agent. Some of these 
genes were validated by RT-PCR (Figure 4.15A) and, in-vivo in tumor bearing mice treated with 
inhibitors, by confocal microscopy (Figure 4.15B).  
 
 
 
Figure 4.15: Validation of selected genes in HD-MyZ cell line treated with perifosine and/or sorafenib for 24 
hours. (A) The bar chart shows the gene expression patterns (presented as fold change with respect to control 
levels) of selected significantly regulated genes calculated using real-time RT-PCR analysis. The down-
regulated genes selected were CCNE1, and CDC25A while the up-regulated genes were TRIB3, DDIT4, and 
PLEKHF1. All PCR data were normalized to the intensity of #2-microglobulina as a housekeeping gene. Each 
statistical error bar (± SEM) represents three independent experiments. (B) NOD/SCID mice bearing HD-MyZ 
SC tumor nodules 100 mg in weigth were randomly assigned to receive perifosine (30 mg/kg/5die, PO) and/or 
sorafenib (90 mg/kg/5die, IP) or control vehicle. Representative confocal images of tumors from untreated and 
treated animals processed by double immunofluorescence staining. Cell nuclei (blue) were detected by TO-
PRO-3; DDIT-4 expression (red) was detected by anti-DDIT-4 antibody and Alexa Fluor 568-conjugated 
secondary antibody. Objective lens, original magnification: 1.0 NA oil objective, 40x 
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4.6.1 Perifosine/sorafenib induces apoptosis requiring TRIB3 up-regulation 
 
The experiments performed above highlighted many differences between HD-MyZ, L-540 and 
HDLM-2 cell types in response to perifosine/sorafenib. Interestingly, only one gene, tribbles 
homology 3 (TRIB3), was significantly modulated by the combined treatment in the two most 
responsive cell lines (HD-MyZ and L-540, Figure 4.14). Tribbles homology 3 (TRB3 or TRIB3) 
became of interest due to its array of binding partners such as mitogen-activated protein kinase 
family members211 and AKT.212 Furthermore, TRIB3 expression was enanched in HD-MyZ and L-540 
tumor nodules after perifosine/sorafenib treatment (Figure 4.16), with no expression observed in 
HDLM-2 (Figure 4.16). 
 
 
Figure 4.16: In vivo modulation of TRIB3 by perifosine/sorafenib treatment in HL cells. NOD/SCID mice 
bearing HD-MyZ, L-540 and HDLM-2 tumor nodules 100 mg in weigth were randomly assigned to receive 
perifosine (30 mg/kg/mouse, PO) or sorafenib (90 mg/kg/mouse, IP) (alone or in combination) or control 
vehicle. Representative confocal images of tumors from untreated and treated animals processed by double 
immunofluorescence staining. Cell nuclei (blue) were detected by TO-PRO-3; TRIB3 expression (red) was 
detected by anti-TRIB3 antibody and Alexa Fluor 568-conjugated secondary antibody. Objective lens, original 
magnification: 1.0 NA oil objective, 40x. 
 
In order to define whether perifosine/sorafenib induces apoptosis requiring up-regulation of TRIB3, 
we silenced the expression of TRIB3 using TRIB3 siRNA and then examined cell sensitivity to 
perifosine/sorafenib combined treatment. By Western blotting, we detected substantially reduced 
levels of TRIB3 (43% reduction) in L-540 cells transfected with TRIB3 siRNA compared with those in 
control siRNA-transfected cells (Figure 4.17A), indicating successful TRIB3 knockdown. 
Accordingly, a 50% increase in cell viability was also enhanced in TRIB3 siRNA-transfected cells 
compared with control siRNA-transfected cells (Figure 4.17B). These results indicate that TRIB3 up-
regulation is involved in perifosine/sorafenib-induced apoptosis.  
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Figure 4.17: Demonstration of the role of TRIB3 induction in perifosine-induced apoptosis in HL cells. (A-B) 
TRIB3 siRNA (100 nM) and also with control siRNA (100 nM) were transfected in L-540 cells overnight. After 
transfection, the cells were treated with perifosine or sorafenib or in combination for 48 – 72 hours. (A) After 48 
hours the efficiency of TRIB3 siRNA inhibition was analyzed by Western blotting using TRIB3-specific 
antibodies. Equal protein loading was confirmed by blotting for β-actin. Each lane were subjected to western 
immunoblot analysis as described under the Material and Methods section. Representative blots are shown. 
Experiments were repeated twice with similar results. (B) Viable cell counts were obtained as described in 
Materials and Methods. Mean (± SEM) values refer to three independent experiments. * P <.001 compared with 
control siRNA. 
 
4.7 IN VIVO ACTIVITY OF PERIFOSINE AND SORAFENIB IN HL TUMOR 
MODELS 
 
Six- to eight-week-old NOD/SCID mice with a body weight of 20 to 25 g were xenografted with 
HD-MyZ, L-540, or HDLM-2 cell lines. Mice were inoculated intravenously (IV) with HD-MyZ (1.8 x 
106 cells/mouse). After 3 days HD-MyZ injection, mice were randomized in four groups 
(n=5/group, for a total of two different experiments) to receive per os (PO) injections of perifosine 
(7.5 mg/kg/mouse/5die/5weeks) and/or intraperitoneal (IP) injections of sorafenib (60 
mg/kg/mouse/5die/5weeks), or control NaCl solution 0.9%. Endpoint of in vivo IV experiments 
was death.  
 
HD-MyZ (5 × 106 cells/mouse), L-540 and HDLM-2 (25 × 106 cells/mouse) cells were inoculated 
subcutaneously (SC) in the right flank of each mouse. When tumor volume reached approximately 
100 mg in weight (see Meterial and Methods for details), mice were randomly assigned to receive 
either a short- or long-term treatment with perifosine and/or sorafenib or control vehicle. The short-
term treatment was used to assess necrotic and apoptotic areas, whereas the long-term treatment 
was used to assess tumor growth inhibition. Mice were checked twice weekly for tumor appearance, 
body weight measurements and toxicity. Each experiment was performed on at least two separate 
occasions, using five mice per treatment group. 
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4.7.1 Combining perifosine with sorafenib increases median surviaval of 
NOD/SCID mice xenografted with HL tumors 
  
To determine whether the combined perifosine/sorafenib treatment could enhance the anti-
lymphoma activity not only in vitro but also in vivo, a xenograft model of Hodgkin lymphoma was 
used. The antitumor activity of perifosine/sorafenib was investigated in NOD/SCID mice 
xenografted intavenously (IV) with HD-MyZ. HD-MyZ cell line was selected for in vivo studies due 
to its tumorigenic features which mimick disseminated tumor with infiltrative and destructive 
growth. NOD/SCID mice inoculated IV with 1.8 x 106 HD-MyZ cells, received a 25-day treatment 
with perifosine (7.5 mg/kg/day, 5 days per week for 5 weeks, PO), sorafenib (60 mg/kg/day, 5 
days per week for 5 weeks, IP), the combined treatment or vehicle control. Drug treatment was 
started 3 days after tumor inoculation. No significant changes in weight or other signs of potential 
toxicity were observed during treatment with perifosine, sorafenib or the combined treatment 
(Figure 4.18).  
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Mice weight of each group during the treatment. HD-MyZ cells line (1.8 × 106 cells/mouse) were 
injected IV into NOD/SCID mice. Mice received control vehicle (black circle), perifosine (7.5 
mg/kg/mouse/5die/5weeks, PO, green square), sorafenib (60 mg/kg/mouse/5die/5weeks, IP, blue triangle) 
or the combined treatment (red circle). Treatment started at day 3 from tumor inoculation. Each treatment 
group contained 10 mice. The weights of treated mice did not significantly change over the course of treatment 
with perifosine and/or sorafenib. Points, average mouse weight; bars, SEM. 
 
Using Kaplan-Meier curves and log-rank analysis, there was no statistically significant difference in 
the mean overall survival of mice treated with perifosine over controls, whereas a modest increase 
of median survival over controls was detected in sorafenib-treated mice (45 vs 54 days, P <.03) 
(Figure 4.19). In contrast, the combined treatment with perifosine plus sorafenib resulted in a 
significant increase of median survival as compared to controls (45 vs 81 days, P <.0001) as well as 
mice receiving perifosine (49 vs 81, P <.03) or sorafenib alone (54 vs 81, P <.007) (Figure 4.19). The 
significant enhancement of therapeutic activity of the combined perifosine/sorafenib treatment over 
single drug-treatment was further supported by an increase up to 25% of animals being alive and 
well at the end of the 200-day observation period (Figure 4.19). 
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Figure 4.19: Perifosine in combination with sorafenib produces robust efficacy against HL xenografts in 
NOD/SCID mice. HD-MyZ cells line (1.8 × 106 cells/mouse) were injected IV into NOD/SCID mice. Mice 
received control vehicle (black circle), perifosine (7.5 mg/kg/mouse/5die/5weeks, PO, green square), 
sorafenib (60 mg/kg/mouse/5die/5weeks, IP, blue triangle) or the combined treatment (red circle). Treatment 
started at day 3 from tumor inoculation. Each treatment group contained 10 mice. Kaplan-Meyer estimates of 
overall survival of NOD/SCID mice xenografted with HD-MyZ cell line. Survival was measured from the day 
of xenografting. * P <.0001 compared to controls. 
 
4.7.2 In vivo tumor growth inhibition by perifosine in combination with 
sorafenib 
  
The in vivo antitumor activity of perifosine in combination with sorafenib was investigated in 
NOD/SCID mice bearing subcutaneous L-540 and HDLM-2 tumor nodules. Treatments with 
perifosine without and with sorafenib were started when tumor volume reached approximately 100 
mg in weight and tumor size was monitored until mice were sacrificed due to extensive disease. The 
tumors were measured with calipers, and their weights were calculated using the formula: (a × 
b2)/2, where a and b represented the longest and shortest diameters, respectively. Antitumor 
efficacy was measured as tumor growth inhibition (TGI) defined as [1 - (T/C) × 100], where T and C 
are the mean tumor weight in the treated and untreated control groups, respectively. Each 
experiment was performed on at least two separate occasions, using five mice per treatment group. 
 
In contrast with in vitro experiments showing significant levels of perifosine and sorafenib activity 
against the responsive L-540 cell line, in vivo perifosine and sorafenib as single treatments failed to 
affect the subcutaneous growth of L-540 nodules, as compared to vehicle-treated controls (2 ± 0.2 vs 
2.4 ± 0.1 g and 2.6 ± 0.4 vs 2.4 ± 0.1 g, P >0.5, respectively) (Figure 4.20). Notwithstanding their lack 
of activity when used as single treatments, combination of perifosine with sorafenib significantly 
reduced the growth of L-540 nodules by 42% over controls (1.5 ± 0.5 vs 2.6 ± 0.4 g, P <.0001), 35% 
over perifosine alone (1.5 ± 0.5 vs 2.3 ± 0.7 g, P <.0001), and 46% over sorafenib alone (1.5 ± 0.5 vs 2.8 
± 0.7 g, P <.0001) (Figure 4.20). 
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Figure 4.20: Perifosine plus sorafenib inhibits L-540 cell growth in vivo. NOD/SCID mice were SC inoculated 
with L-540 tumor cells (25 x 106 cells/mouse). Treatments were initiated on day 7, when all groups had tumor 
nodules reached approximately 100 mg in weight. Control vehicle (black circle), perifosine (15 mg/kg/die, 5 
days per 3 weeks, PO, green square), sorafenib (30 mg/kg/die, 5 days per 3 weeks, IP, blue triangle) and the 
combined treatment (red circle). Mice were checked twice weekly for tumor appearance, tumor dimensions, 
body weight, and toxicity. Each experiment was performed on at least two separate occasions, using 5 mice per 
treatment group. Green arrows indicate perifosine treatment administration; blue arrows indicate sorafenib 
treatment administration. Treatment duration is indicated by horizontal capped black lines (days 7 – 25 for L-
540 xenograft). Mean (± SD) tumor weight data are shown. * P <.0001 compared to controls and sorafenib, ° P 
<.01 compared to sorafenib and ≠ P <.05 compared to perifosine. 
 
The growth of perifosine-resistent HDLM-2 tumor nodules was uneffected by both perifosine or 
sorafenib alone as compared to controls (0.7 ± 0.2 vs 0.8 ± 0.2 g and 0.8 ± 0.2 vs 0.8 ± 0.2 g, P >0.5, 
respectively) (Figure 4.21). Furthermore, the combined treatment perifosine/sorafenib did not 
reduced the growth of HDLM-2 tumor nodules as compared to controls (0.8 ± 0.2 vs 0.8 ± 0.2 g, P 
>0.5) (Figure 4.21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Perifosine plus sorafenib doesn’t affect HDLM-2 cell growth in vivo. NOD/SCID mice were SC 
inoculated with HDLM-2 tumor cells (25 x 106 cells/mouse). Treatments were initiated on day 11, when all 
groups had tumor nodules reached approximately 100 mg in weight. Control vehicle (black circle), perifosine 
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(15 mg/kg/die, 5 days per 3 weeks, PO, green square), sorafenib (30 mg/kg/die, 5 days per 3 weeks, IP, blue 
triangle) and the combined treatment (red circle). Mice were checked twice weekly for tumor appearance, 
tumor dimensions, body weight, and toxicity. Each experiment was performed on at least two separate 
occasions, using 5 mice per treatment group. Green arrows indicate perifosine treatment administration; blue 
arrows indicate sorafenib treatment administration. Treatment duration is indicated by horizontal capped black 
lines (days 11 – 29 for HDLM-2 xenograft). Mean (± SD) tumor weight data are shown.  
 
4.7.3 In vivo perifosine/sorafenib combined treatment induces necrosis events  
 
To elucidate the mechanism(s) of perifosine/sorafenib-induced anti-lymphoma activity, tumor-
bearing mice were treated for 5 days with vehicle control, perifosine (30 mg/kg/day), and sorafenib 
(90 mg/kg/day), used alone or in combination. Treatment was started when tumor volumes 
reached approximately 100 mg in weight (i.e., 10 days after tumor inoculation) and three hours after 
the last treatment, nodules were excised and appropriately stained. Hematoxylin and eosin and 
TUNEL staining of both HD-MyZ and L-540, but not HDLM-2 tumors excised from mice receiving 
perifosine in combination with sorafenib showed the presence of extensive necrotic areas within 
tumor tissue, which were much more widespread as compared to tumors from untreated, 
perifosine- or sorafenib-treated mice (Figure 4.22).  
 
Figure 4.22: Quantification of tumor necrosis within entire tumor sections. NOD/SCID mice bearing SC tumor 
nodules 100 mg in weight were randomly assigned to receive a 5-day treatment with perifosine (30 mg/kg/die, 
PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. Representative histological images of entire 
tumors sections from mice receving the different treatments are shown. Tumor tissue morphology were 
detected by hematoxylin and eosin (H&E) staining. Tumor necrotic areas were detected by TUNEL staining 
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and revealed as brown areas using 3,3’-diaminobenzidine for light microscopy analysis. Objective lens, original 
magnification: 0.08 NA dry objective, 2x.  
 
An objective quantification of tumor necrosis in entire tumor sections following TUNEL staining 
was achieved by a computer-aided imaging analysis using ImageJ software (Figure 4.23-25). HD-
MyZ tumors from mice treated with perifosine or sorafenib alone was not able to induce significant 
tumor necrosis over controls (20.4 ± 2.6% vs 20.7 ± 4.4% vs 20.8 ± 3.1%, P >.05) (Figure 4.23), whereas 
the combined treatment resulted in a 2-fold increase in tumor necrosis compared to single 
treatments (38.8 ± 9.7% vs 20.4 ± 2.6% vs 20.7 ± 4.4%, P <.0001) (Figure 4.23).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Quantification of tumor necrosis within entire HD-MyZ tumor sections. NOD/SCID mice bearing 
SC tumor nodules 100 mg in weight were randomly assigned to receive a 5-day treatment with perifosine (30 
mg/kg/die, PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. After counterstaining with 
hematoxylin, sections were analyzed using ImageJ for quantification of tumor necrosis percentage. 
Quantification of HD-MyZ necrotic areas by ImageJ analysis on digitally acquired tissue sections stained with 
TUNEL. At least three sections from different animals were analyzed per treatment group. The boxes extend 
from the 25th to the 75th percentile, the lines indicate the median values and the wiskers indicate the range of 
values. * P <.0001 compared to controls, and ≠ P <.0001 compared to single treatments. 
 
In addition, TUNEL staining of L-540 tumor sections from untreated, and perifosine-treated mice 
revealed a homogeneous mass of viable cells with necrotic areas accounting only for 2.7 ± 0.6%, and 
3.9 ± 1.9% of total tissue, respectively (Figure 4.24). In contrast, tumors from sorafenib-treated mice 
displayed a significant increase of necrotic areas as compared to controls (7 ± 1.3% vs 2.7 ± 0.6%, P 
<.01) (Figure 4.24). After perifosine/sorafenib-tretment, the percentages of necrotic areas per tissue 
section ranged from 17% to 27%, resulting in a mean 8-fold increase over controls (22.2 ± 3.9% vs 2.7 
± 0.6%, P <.0001), and a 1.4 to 2.6-fold increase over perifosine or sorafenib-treated mice, 
respectively (22.2 ± 3.9% vs 3.9 ± 1.9% vs 7 ± 1.3%, P <.0001) (Figure 4.24).  
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Figure 4.24: Quantification of tumor necrosis within entire L-540 tumor sections. NOD/SCID mice bearing SC 
tumor nodules 100 mg in weight were randomly assigned to receive a 5-day treatment with perifosine (30 
mg/kg/die, PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. After counterstaining with 
hematoxylin, sections were analyzed using ImageJ for quantification of tumor necrosis percentage. 
Quantification L-540 necrotic areas by ImageJ analysis on digitally acquired tissue sections stained with 
TUNEL. At least three sections from different animals were analyzed per treatment group. The boxes extend 
from the 25th to the 75th percentile, the lines indicate the median values and the wiskers indicate the range of 
values. * P <.0001 and # P <.01, compared to controls. ≠ P <.0001 compared to single treatments. 
 
In accordance with the absence of in vitro responce, treatment with perifosine in mice bearing 
perifosine-resistant HDLM-2 tumors failed to induced any significant increase in tumor necrosis 
compared to untreated controls (28.9 ± 3.9% vs 26.2 ± 12%, P >.05) (Figure 4.25). Interestingly, 
HDLM-2 tumors treated with sorafenib showed a significant increase in tumor necrosis as compared 
to controls (68.9 ± 7.6% vs 26.2 ± 12%, P <.0001) (Figure 4.25). Similarly, HDLM-2 tumors from mice 
receiving perifosine in combination with sorafenib resulted in a 2-fold increase in tumor necrosis 
compared to controls (52.9 ± 3.7% vs 26.2 ± 12%, P <.0001) (Figure 4.25), but failed to show any 
increase in tumor necrosis over sorafenib-treated mice (52.9 ± 3.7% vs 68.9 ± 7.6%, P >.05) (Figure 
4.25). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25: Quantification of tumor necrosis within entire HDLM-2 tumor sections. NOD/SCID mice bearing 
SC tumor nodules 100 mg in weight were randomly assigned to receive a 5-day treatment with perifosine (30 
mg/kg/die, PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. After counterstaining with 
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hematoxylin, sections were analyzed using ImageJ for quantification of tumor necrosis percentage. 
Quantification of HDLM-2 necrotic areas by ImageJ analysis on digitally acquired tissue sections stained with 
TUNEL. At least three sections from different animals were analyzed per treatment group. The boxes extend 
from the 25th to the 75th percentile, the lines indicate the median values and the wiskers indicate the range of 
values. * P <.0001 compared to controls. 
 
4.7.4 Perifosine and sorafenib combined treatment enhances direct tumor cell 
killing in HL xenograft tumors 
 
Besides a significant increase of necrotic areas, TUNEL staining of both HD-MyZ and L-540 tumors 
from mice treated with perifosine and sorafenib also revealed a strong increase of tumor cell death 
(TUNEL+ cells) as compared with single treatments as well as control animals (Figure 4.26). 
Quantification of tumor cell death within entire tumor sections was performed using ImageJ 
software (Figure 4.27-29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26: Perifosine in combination with sorafenib results in direct tumor cell killing in vivo. NOD/SCID 
mice bearing SC tumor nodules 100 mg in weight were randomly assigned to receive a 5-day treatment with 
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perifosine (30 mg/kg/die, PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. Three hours after the 
last treatment tumor nodules were harvested and analyzed for tumor apoptosis. Tumor apoptotic cells were 
detected by TUNEL staining and revealed as brown nuclei using 3,3’-diaminobenzidine for light microscopy 
analysis. Objective lens, original magnification: 0.75 NA dry objective, 20x.  
 
TUNEL staining of HD-MyZ nodules treated with perifosine failed to show any rise in tumor cell 
death over controls (0.9 ± 0.6% vs 1.1 ± 0.7%, P >.05) (Figure 4.27). By contrast, sorafenib alone or 
combined with perifosine increased TUNEL+ cells over controls by 1.6- and 2.3-fold, respectively 
(1.7 ± 1.1% vs 1.1 ± 0.7%, P <.0001; 2.2 ± 1.7% vs 1.1 ± 0.7%, P <.0001) (Figure 4.27).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: Perifosine in combination with sorafenib results in direct HD-MyZ tumor cell killing in vivo. 
NOD/SCID mice bearing SC tumor nodules 100 mg in weight were randomly assigned to receive a 5-day 
treatment with perifosine (30 mg/kg/die, PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. Three 
hours after the last treatment tumor nodules were harvested and analyzed for tumor apoptosis. After 
counterstaining with hematoxylin, sections were analyzed using ImageJ for quantification of apoptotic tumor 
cells percentage. Quantification of HD-MyZ apoptotic cells by ImageJ analysis on digitally acquired tissue 
sections stained with TUNEL. At least three sections from different animals were analyzed. Each dot represents 
the value obtained from the analysis of a single tissue field and the lines indicate the mean values.  * P <.0001 
compared to controls. # P <.0001 compared to single treatments. 
 
In L-540 tumors, perifosine or sorafenib as single agents produced respectively a 1.6- (1.6 ± 0.7% vs 1 
± 0.5%, P <.0001) and 1.4-fold increase (1.4 ± 0.8% vs 1 ± 0.5%, P <.0001) of TUNEL+ cells over 
controls (Figure 4.28). Perifosine/sorafenib combined treatment enhanced the anti-tumor activity of 
single agents, causing a 2-fold increase of L-540 cell death over controls (2 ± 0.9% vs 1 ± 0.5%, P 
<.0001) (Figure 4.28).  
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Figure 4.28: Perifosine in combination with sorafenib results in direct L-540 tumor cell killing in vivo. 
NOD/SCID mice bearing SC tumor nodules 100 mg in weight were randomly assigned to receive a 5-day 
treatment with perifosine (30 mg/kg/die, PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. Three 
hours after the last treatment tumor nodules were harvested and analyzed for tumor apoptosis. After 
counterstaining with hematoxylin, sections were analyzed using ImageJ for quantification of apoptotic tumor 
cells percentage. Quantification of L-540 apoptotic cells by ImageJ analysis on digitally acquired tissue sections 
stained with TUNEL. At least three sections from different animals were analyzed. Each dot represents the 
value obtained from the analysis of a single tissue field and the lines indicate the mean values.  * P <.0001 
compared to controls. # P <.0001 compared to single treatments. 
 
In accordance with all results described above, TUNEL staining of HDLM-2 nodules treated with 
perifosine didn’t show any rise in tumor cell death over controls (0.9 ± 0.4% vs 0.9 ± 0.5%, P >.05) 
(Figure 4.29). In addition, both sorafenib used as single agent (0.8 ± 0.4% vs 0.9 ± 0.5%, P >.05) and 
the combined-treatment (0.8 ± 0.5% vs 0.9 ± 0.5%, P >.05) failed to potentiate anti-tumor activity over 
controls (Figure 4.29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29: Perifosine in combination with sorafenib doesn’t induce HDLM-2 tumor cell killing in vivo. 
NOD/SCID mice bearing SC tumor nodules 100 mg in weight were randomly assigned to receive a 5-day 
treatment with perifosine (30 mg/kg/die, PO) and/or sorafenib (90 mg/kg/die, IP), or control vehicle. Three 
hours after the last treatment tumor nodules were harvested and analyzed for tumor apoptosis. After 
counterstaining with hematoxylin, sections were analyzed using ImageJ for quantification of apoptotic tumor 
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cells percentage. Quantification of HDLM-2 apoptotic cells by ImageJ analysis on digitally acquired tissue 
sections stained with TUNEL. At least three sections from different animals were analyzed. Each dot represents 
the value obtained from the analysis of a single tissue field and the lines indicate the mean values.   
 
Taken together, these data suggest that although perifosine and sorafenib alone exhibit modest anti-
HL effects in vitro, they are only marginally effective as monotherapy in vivo. However, combining 
perifosine with sorafenib results in significant HL tumor growth inhibition in vivo, an observation 
of potential clinical utility. 
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5. DISCUSSION 
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The generally cytoprotective role played by the MEK/ERK1/2 and PI3-K/Akt signaling cascades 
has focused attention on the use of MEK and PI3-K/Akt inhibitors to enhance the activity of 
conventional cytotoxic agents.213 However, it has been shown that simultaneous interruption of two 
complementary signaling pathways potently induces apoptosis in transformed cells.214 In this 
context, concomitant interruption of the MEK/ERK1/2 (i.e., by sorafenib) and PI3-K/Akt (i.e., by 
perifosine) pathways represents an effective treatment option in Hodgkin lymphoma. The resulting 
data provide compelling evidence that combining perifosine with sorafenib produces an effective 
cytotoxic and cytostatic combination, both in vitro and in vivo. We therefore propose that additional 
exploration of this combination in clinical trials is warranted. 
 
The present findings indicate that coadministration of clinically relevant perifosine and sorafenib 
results in a striking increase in mitochondrial injury, gene expression changes, apoptosis, and in a 
marked reduction of the viability, supported by decreased S-phase fraction, in HL responsive cells. 
These events are associated with multiple perturbations of diverse cell signaling pathways including 
inactivation of Akt and MEK/ERK1/2, inactivation of Mcl-1, an increase in cytochrome c and 
apoptosis-inducing factor (AIF) release, and a marked conformational change in Bax accompanied 
by translocation to the mitochondrial membrane. Such findings are consistent with the results of 
several recent reports indicating that a variety of agents that perturb signal transduction pathways, 
including proteasome, HDAC, and RAF/MAPK inhibitors are able to enhance PI3-K/Akt 
inhibitors-mediated lethality, culminating in marked anti-tumor synergism.215-217 However, this 
study identified a putative role for TRIB3, an endogenous inhibitor of Akt, in mediating perifosine- 
and sorafenib-potentiated apoptosis.  
 
The effects of perifosine/sorafenib combined treatment was evaluated in vitro and in vivo using 
three well established Hodgkin lymphoma cell lines (HD-MyZ, L-540, HDLM-2). Despite the close 
resemblance in immunophenotype, these cell lines are not generally accepted as being truly derived 
from H or RS cells in all instances. Indeed, HD-MyZ cell line differs strikingly from in situ HRS cells 
as it expresses the macrophage associated CD68 antigen and lacks expression of CD30 and CD15 as 
well as rearrangement of immunoglobulin or TCR genes.218 Due to the fact that H or RS cells account 
only for a minority of cells within the bystander cells in Hodgkin disease (HD) tissue and that many 
attempts to cultivate H or RS cells failed, one has to bear in mind that these cell lines, which were 
successfully derived from HD, might only reflect a certain aspect of the disease. 
 
The Akt pathway plays an important anti-apoptotic role; furthermore, disruption of the PI3-K/Akt 
cascade has been implicated in perifosine-mediated lethality in various tumor cells.146,219 Consistent 
with these results, exposure to perifosine inactivated Akt and reduced phosphorylation of some of 
its downstream targets (eg, S6) in HL cells; however, low expression of Akt significantly diminished 
perifosine-mediated lethality in HDLM-2 cells. Interestingly, low activation of Akt failed to 
attenuate sorafenib-mediated lethality despite dramatically reducing apoptosis induced by 
perifosine or the perifosine/sorafenib regimen in HDLM-2 cells. Such observations are consistent 
with previous findings demonstrating a connection between perifosine efficacy and PI3-K/Akt 
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pathway activation.220 It is tempting to speculate that HL cells, particularly those exhibiting Akt 
dysregulation, may be addicted to these pathways, thus accounting for their susceptibility to this 
regimen. However, it is clear that larger cell lines number will be necessary to define the 
relationship between susceptibility to the perifosine/sorafenib regimen and both the basal signaling 
status. Furthermore, PI3-K/Akt and MEK/ERK1/2 pathways activation status may allow baseline 
selection of patients most likely to respond to perifosine and sorafenib alone or in combination with 
other therapies. 
 
In several recent studies perifosine and sorafenib have been shown to be potent inhibitors of the 
MAPK-pathway.221,222 Overall, perifosine in combination with sorafenib significantly affected the 
MAPK signaling pathway in the HD-MyZ and L-540 sensitive cell lines, whereas the HDLM-2 cell 
line was substantially unaffected by perifosine/sorafenib treatment. Although coadministration of 
sorafenib did not abrogate MAPK activation in cells exposed to a low, minimally toxic concentration 
of perifosine, it did reduce activation to levels well below those observed in cells exposed to 
perifosine alone, suggesting that diminution in MAPK activation by sorafenib promotes perifosine 
lethality by blocking a cytoprotective response. 
 
Another controversial point is the mechanism of perifosine and sorafenib-mediated cell death. 
Studies demonstrating either dependent or independent CD95-mediated apoptotic effects150,223 have 
been reported, along with studies describing autophagy224,225 as well as caspase-dependence226 or 
caspase-independence219,227 of perifosine and sorafenib-mediated cell death. The controversial role of 
these events in molecular targeted drugs-induced cell death might be due to the use in different 
studies of different cell models. Perifosine and sorafenib, either alone or in combination, failed to 
induce any processing of the caspases-3, 8, and 9, as well as PARP, which is typical of caspase-
dependent apoptosis, in HL cells. In addition, we did not detect any effect of the pan-caspase 
inhibitor Z-VADfmk on perifosine/sorafenib-induced cell death suggesting the involvement of 
caspase-independent pathways. It has been shown that a conformational change in Bax is required 
for its proapoptotic activity, manifested by the translocation of cytochrome c, Smac/DIABLO, and 
AIF from the mitochondria to the cytosol.228 The present studies showed that combined exposure of 
L-540 cells to perifosine and sorafenib resulted in a marked increase in Bax conformational change, 
accompanied by extensive translocation of Bax to the mitochondria and conseguent marked cell 
death. It is also notable that we did not observe induction of apoptosis or activation of cleaved 
caspase in response to perifosine and sorafenib used as single-agents or in combination in HD-MyZ 
cell line, suggesting that the mechanism of action of perifosine and sorafenib in HD-MyZ is 
predominantly cytostatic and not cytotoxic and may be mediated by G2 arrest. It is currently 
thought that the anti-apoptotic activity of Mcl-1 primarily involves interactions with Bak.229 In the 
present study, the anti-apoptotic Bcl-2 family member Mcl-1 downregulation in all likelihood plays 
an important functional role in synergistic induction of HL cell death by simultaneous interruption 
of the MEK/ERK1/2 and PI3-K/Akt pathways, in responsive cell lines. Mcl-1 expression is 
regulated by ERK1/2 at the transcriptional level and at the posttranslational level through direct 
phosphorylation on threonine 163, which attenuates Mcl-1 degradation.230 Conversely, GSK-3, a 
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kinase inactivated by Akt, phosphorylates Mcl-1 on serine 159, an event that promotes Mcl-1 
degradation.231 Consequently, both transcriptional and posttranscriptional mechanisms may be 
involved in Mcl-1 down-regulation after perifosine/sorafenib exposure.  
 
Perifosine and sorafenib trigger mediators of endoplasmic reticulum (ER) stress-induced apoptosis 
in HL cells, consistent with previous reports.216,232 A potential mechanism for increased expression of 
TRIB3 is ER stress.233 Further investigation highlighted the importance of TRIB3 in mediating HL cell 
survival. Significantly greater amounts of TRIB3 were detected in HL cells relative to 
perifosine/sorafenib exposure both in vitro and in vivo. Consistent with this, downregulation of 
TRIB3 with siRNA significantly reduced perifosine/sorafenib-induced anti-lymphoma effects, 
indicating that the activation of the pseudokinase exerts a major role in the mechanism of action of 
perifosine and sorafenib combined treatment. It has been reported that TRIB3 appears necessary for 
MAP kinase pathway function and is inhibitory at high levels,211 in addition TRIB3 binds Akt 
preventing its phosphorylation and activation.212 We can speculate that TRIB3, once overexpressed 
by perifosine/sorafenib treatment, could enhances perifosine and sorafenib single agent-activity by 
simultaneous interruption of the PI3-K/Akt and MEK/ERK1/2 pathways leading to a pronounced 
Akt, ERK and Mcl-1 inactivation and a striking increase in mitochondrial dysfunction (Figure 5.1). 
Together, such findings show that two caspase-independent apoptotic pathways, one from the 
mitochondrion and one from the endoplasmic reticulum, are coactivated during 
perifosine/sorafenib treatment and cooperate to trigger Hodgkin lymphoma cell death. 
 
Figure 5.1: Proposed mechanistic model by which dual disruption of PI3-K/Akt and MEK/ERK1/2 pathways 
induces apoptosis in HL cells. Dual disruption of the MEK/ERK1/2 and PI3-K/Akt pathways results in TRIB3 
accumulation, most likely through caspase-idependent cell death. In addition, this treatment also diminishes 
Akt, ERK and Mcl-1 phosphorilated protein levels, leading to Bax confomational change and activation, 
mitochondrial outer membrane permeabilization, release of cytochrome c, and AIF. 
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Based on the promising in vitro data, perifosine/sorafenib combined treatment also showed potent 
in vivo tumoricidal efficacy. Perifosine and sorafenib showed minimal efficacy in vivo when used as 
single agents. However, the combination resulted in improved efficacy; survival was significantly 
prolonged in HD-MyZ tumor-bearing mice, and a substantial percentage remained tumor free at the 
end of the 200-day observation period. Moreover, perifosine/sorafenib reduced L-540 tumor growth 
(by 42%), but not HDLM-2 resistent xenograft model. Lymphoma growth inhibition developed 
slowly and progressively, usually reaching the level of objective regression after three weeks of 
dosing. While a 5-day treatment with perifosine/sorafenib resulted in early induction of extensive 
tumor necrosis (2 to 8-fold) only in responsive HD-MyZ and L-540 xenograft models. In vitro 
perifosine and sorafenib single agents-activity partially correlated with in vivo effects, likely due to 
a much more complex scenario occurring in xenograft models which essentially involves an active 
role of microenvironmental cells in modulating tumor cell growth. 
 
HL results in approximately 1,300 deaths per year in the United States.234 Owing to the limitations of 
the available therapy, there is an urgent need for new therapeutic options for relapsed HL patients. 
The signaling pathways that we examined are the two pathways most commonly activated in HL. 
The drugs that we employed to target these pathways are in active clinical development. The 
preclinical activity that we observed justifies further investigation and lays groundwork for phase I-
II studies combining perifosine and sorafenib in HL. 
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The proposed project was aimed at investigating in vitro and in vivo the activity and mechanism(s) 
of action of perifosine in combination with sorafenib by using three HL cell lines (HD-MyZ, L-540, 
HDLM-2). Despite perifosine and sorafenib used as single agents had modest effects on HL cells, 
perifosine/sorafenib combination resulted in potent anti-HL activity both in vitro and in vivo.  
 
In 2 of 3 HL cell lines, the combined perfosine/sorafenib treatment induced potent antitumor effects 
in vitro: 
• Synergistic cell growth inhibition and cell death induction in HD-MyZ and L-540 cell lines, 
but not in HDLM-2 cell line 
• Blocking cell cycle 
• Down-modulating MAPK and PI3K/Akt pathways 
• Caspase-independent apoptosis associated with severe mitochondrial dysfunction 
• Modulating genes involved in amino acid metabolism, cell cycle, DNA replication and cell 
death 
• Overexpressing tribbles homologues 3 (TRIB3) 
 
Effects of the combined perifosine/sorafenib treatment in vivo: 
• HD-MyZ – Significant increase of survival (45 vs 81 days, as compared to controls) 
• HD-MyZ – 25% tumor-free mice at the end of the 200-day observation period  
• No significant changes in weight or other signs of potential toxicity during perifosine 
and/or sorafenib treatments  
• L-540 – Reduction of tumor volumes as compared to controls (by 42%), perifosine (by 35%) 
or sorafenib (by 46%) alone 
• HD-MyZ and L-540 but not HDLM-2: 
- Tumor necrosis (2- to 8-fold, P ≤.0001) 
- Tumor apoptosis (2- to 2.5-fold, P ≤.0001) 
 
Based on these preclinical data, a phase II trial exploring the clinical activity of perifosine/sorafenib 
in HL is currently ongoing. 
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